Pes planus, or flat feet, is a common concern addressed during well-child visits. Many parents express concern more because of the appearance of the feet than actual symptomatology. But what is within the realm of normal and what is beyond?

Ninety percent of clinic visits for foot problems are for flat feet.¹ Historically, the treatment of flat feet was wearing orthopedic shoes that were unappealing, so parents fear that is the fate of their child. Although the exact incidence rate of flat feet has not been determined, it clearly is quite common. Other contributing factors are joint hypermobility, obesity, and age. All children under the age of 2 years have flat feet because of the fat pad that is present. By the age of 10 years, this fat pad regresses and the normal arch is formed.

Dr. Pearce is a pediatrician in Frankfort, Ill. She said she had no relevant financial disclosures. Email her at [email protected].

References

1. Iran J Pediatr. 2013 Jun;23(3):247-60.

2. J Child Orthop. 2010;4(2):107-21.

Pes planus, or flat feet, is a common concern addressed during well-child visits. Many parents express concern more because of the appearance of the feet than actual symptomatology. But what is within the realm of normal and what is beyond?

Ninety percent of clinic visits for foot problems are for flat feet.¹ Historically, the treatment of flat feet was wearing orthopedic shoes that were unappealing, so parents fear that is the fate of their child. Although the exact incidence rate of flat feet has not been determined, it clearly is quite common. Other contributing factors are joint hypermobility, obesity, and age. All children under the age of 2 years have flat feet because of the fat pad that is present. By the age of 10 years, this fat pad regresses and the normal arch is formed.

Dr. Pearce is a pediatrician in Frankfort, Ill. She said she had no relevant financial disclosures. Email her at [email protected].

References

1. Iran J Pediatr. 2013 Jun;23(3):247-60.

2. J Child Orthop. 2010;4(2):107-21.

Pes planus, or flat feet, is a common concern addressed during well-child visits. Many parents express concern more because of the appearance of the feet than actual symptomatology. But what is within the realm of normal and what is beyond?

Ninety percent of clinic visits for foot problems are for flat feet.¹ Historically, the treatment of flat feet was wearing orthopedic shoes that were unappealing, so parents fear that is the fate of their child. Although the exact incidence rate of flat feet has not been determined, it clearly is quite common. Other contributing factors are joint hypermobility, obesity, and age. All children under the age of 2 years have flat feet because of the fat pad that is present. By the age of 10 years, this fat pad regresses and the normal arch is formed.

Dr. Pearce is a pediatrician in Frankfort, Ill. She said she had no relevant financial disclosures. Email her at [email protected].

References

1. Iran J Pediatr. 2013 Jun;23(3):247-60.

2. J Child Orthop. 2010;4(2):107-21.

CE/CME No: CR-1705

PROGRAM OVERVIEW
Earn credit by reading this article and successfully completing the posttest and evaluation. Successful completion is defined as a cumulative score of at least 70% correct.

EDUCATIONAL OBJECTIVES
• Differentiate primary hyperparathyroidism (PHPT) from other causes of hypercalcemia and types of hyerparathyroidism.
• Understand the calcium-parathyroid hormone feedback loop.
• Identify appropriate imaging studies and common laboratory findings in the patient with PHPT.
• Describe the common systemic manifestations of PHPT.
• Discuss medical versus surgical management of the patient with PHPT.

FACULTY
Barbara Austin is a Family Nurse Practitioner at Baptist Primary Care, Jacksonville, Florida, and is pursuing a Doctorate of Nursing Practice (DNP) at Jacksonville University.

The author has no financial relationships to disclose.

ACCREDITATION STATEMENT

This program has been reviewed and is approved for a maximum of 1.0 hour of American Academy of Physician Assistants (AAPA) Category 1 CME credit by the Physician Assistant Review Panel. [NPs: Both ANCC and the AANP Certification Program recognize AAPA as an approved provider of Category 1 credit.] Approval is valid for one year from the issue date of May 2017.

Article begins on next page >>

Primary hyperparathyroidism (PHPT) is most often detected as hypercalcemia in an asymptomatic patient during routine blood work. Knowing the appropriate work-up of hypercalcemia is essential, since untreated PHPT can have significant complications affecting multiple organ systems—most notably, renal and musculoskeletal. Parathyroidectomy is curative in up to 95% of cases, but prevention of long-term complications relies on prompt recognition and appropriate follow-up.

Primary hyperparathyroidism (PHPT) is a common endocrine disorder, with a prevalence of approximately 1 to 3 cases per 1,000 persons.¹ PHPT results from inappropriate overproduction of parathyroid hormone (PTH), the primary regulator of calcium homeostasis, and is characterized by hypercalcemia in the setting of an elevated or high-normal PTH level. In most cases of PHPT, unregulated PTH production is caused by a single parathyroid adenoma.

PHPT is the most common cause of hypercalcemia in outpatients and is typically diagnosed following incidental discovery during routine blood work in an asymptomatic patient.^1,2 It is two to three times more common in women than in men, and incidence increases with age; as such, postmenopausal women are most commonly affected.^1,3 PHPT often has an insidious course, and recognition of its clinical manifestations followed by appropriate diagnostic work-up and management are necessary to prevent sequelae.³

PATIENT PRESENTATION

A 68-year-old Caucasian woman presented to her family practice office for a third visit with continued complaints of nontraumatic right lower leg pain. She had previously been diagnosed with tendonitis, which was treated conservatively. The pain failed to improve, and an x-ray was ordered. The x-ray revealed no acute findings but did show osteopenia, prompting an order for a bone mineral density (BMD) test. The BMD test demonstrated osteoporosis, which warranted further investigation. She was prescribed alendronate but refused it, against medical advice, due to concern over potential adverse effects.

Her medical history included hyperlipidemia and hypertension under fair control with lisinopril. She took a low-dose aspirin and flaxseed supplement daily. She also had a history of radiation to the neck, having undergone tonsillar irradiation as a child (a common practice from the 1930s through the 1950s).³ Surgical history included a total hysterectomy with bilateral salpingo-oophorectomy, appendectomy, and tonsillectomy. There was no personal or family history of cancer or endocrine disorders, hypercalcemia, or nephrolithiasis. She was up to date on vaccines and preventive health care measures. Allergies included penicillin and sulfa, both resulting in hives. She was a nonsmoker and did not drink alcohol or engage in illicit drug use.

Review of systems revealed right lower anterior leg pain for four months, characterized as aching, deep, sharp, and throbbing with radiation to the ankle. The pain was worse with activity and prolonged standing; ibuprofen and application of ice provided partial relief. She had experienced some mood changes, including irritability. Physical exam was normal except for dominant right-sided thyromegaly, marked bony point tenderness to the right midshin area, and an antalgic gait.

Laboratory work-up demonstrated elevated PTH, alkaline phosphatase, and calcium levels and a low 25-hydroxyvitamin D [25(OH)D] level (see Table 1). MRI of the right lower leg revealed a grade IV stress fracture (see Figure 1). The elevated serum calcium and PTH levels in addition to abnormal bone density findings led to the diagnosis of PHPT. She was referred to endocrinology and orthopedics for management of PHPT and the stress fracture, respectively, and was placed in an orthopedic walking boot for treatment of the midtibial stress fracture.

The endocrinologist referred her to an otolaryngologist trained in the surgical management of parathyroid adenomas, who ordered a thyroid ultrasound; this study was inconclusive. Additional imaging, including a Tc-99m sestamibi parathyroid scan and CT with contrast of the soft tissue of the neck, was obtained. The parathyroid scan of the neck and upper chest showed retained activity in the right inferior thyroid pole that was concerning for a parathyroid adenoma (see Figure 2). The CT identified a 1.5-cm parathyroid adenoma off the right inferior pole of the thyroid gland (concordant with the parathyroid scan). A single 300-mg parathyroid adenoma was removed from the right inferior pole of the thyroid. The surgery was deemed successful, with intraoperative normalization of the PTH level.

The patient was managed postoperatively by the endocrinologist and was started on calcium and vitamin D supplements. She was prescribed a bisphosphonate, as she had refused to take alendronate following her abnormal BMD test.

DIFFERENTIAL DIAGNOSIS

PHPT and malignancy are the most common causes of hypercalcemia, accounting for 90% of cases.^2,4 A less common cause is familial hypocalciuric hypercalcemia (FHH), a rare benign disorder that imitates PHPT.¹ FHH is ruled out by measurement of 24-hour urine calcium excretion and is characterized by hypocalciuria, defined as a urine calcium level of less than 100 mg/24 h (reference range, 100-300 mg/24 h).² Low calcium excretion can also be identified by a calcium-creatinine excretion ratio.² FHH is a benign autosomal dominant condition caused by a heterozygous mutation of the parathyroid glands’ calcium-sensing receptors.^2,5,6 Young adults with FHH are asymptomatic, and mild hypercalcemia and a normal or slightly elevated PTH are the only laboratory findings.⁴

Measuring PTH levels is key in determining the underlying mechanism of hypercalcemia.^2,7 If the hypercalcemia is not PTH-mediated, malignancy and granulomatous diseases such as sarcoidosis must be considered.^2,7 PTH is suppressed in malignancy except for rare cases of PTH-producing tumors.⁴ Bone metastases cause calcium resorption, and sarcoidosis causes an excess of vitamin D, both resulting in hypercalcemia. Lymphomas and sarcoid granulomas express 1α-hydroxylase, an enzyme that increases the conversion of 25(OH)D to 1,25-dihydroxyvitamin D [1,25(OH)₂D].² When malignancy is suspected, it is appropriate to check a 1,25(OH)₂D level. Thiazide diuretics, such as hydrochlorothiazide, decrease urinary calcium excretion and may result in mild hypercalcemia.² Other possibilities in the differential include hypervitaminosis A or D, dehydration, and excess calcium ingestion, but these are less common.^6,7

CALCIUM REGULATION

The parathyroid glands stem from four poles on the back of the thyroid gland; there are typically four, but the number can vary from two to 11. Secreted PTH, the primary regulator of calcium homeostasis, maintains calcium levels within a narrow physiologic range.^2,8 PTH increases bone resorption, stimulating release of calcium into the blood, and signals the kidneys to increase reabsorption of calcium and excrete phosphorus. It also converts 25(OH)D to 1,25(OH)₂ D, the active form of vitamin D that increases gastrointestinal calcium absorption. In a negative feedback loop, PTH secretion is regulated by serum calcium levels, stimulated when levels are low and suppressed when levels are high (see Figure 3).³ Calcium-sensing receptors, located in the chief cells of parathyroid tissue, are essential to calcium homeostasis. These receptors will either increase or decrease PTH release in response to small changes in blood ionized calcium levels. The receptors also play an independent role in the renal tubules by promoting secretion of calcium in the setting of hypercalcemia.^5,9 The precise regulation of intracellular and extracellular calcium is necessary for normal functioning of physiologic processes, including bone metabolism, hormone release and regulation, neuromuscular function, and cell signaling.⁵

PATHOPHYSIOLOGY

Hyperparathyroidism is defined as excess secretion of PTH and is categorized as primary, secondary, or tertiary based on pathophysiologic mechanisms.

Primary hyperparathyroidism

PHPT is defined as PTH levels that are elevated or inappropriately normal in patients with hypercalcemia and no known history of kidney disease.^2,6 This occurs when the normal feedback mechanism fails to inhibit excess hormone secretion by one or more of the parathyroid glands.⁶ With uninhibited PTH secretion, hypercalcemia will result from increased gastrointestinal absorption and bone resorption.

The most common causes of PHPT are an abnormal proliferation of parathyroid cells (parathyroid adenomas) and parathyroid tissue overgrowth (hyperplasia). PHPT may result from a single parathyroid adenoma (80%-90%), multigland hyperplasia (10%-15%), multiple adenomas (2%-3%), or malignancy (< 1%).^6,10 Adenomas can occur sporadically or less commonly as part of an inherited syndrome.¹ It is estimated that more than 10% of patients with PHPT have a mutation in one of 11 genes associated with PHPT.¹¹ Approximately 5% of PHPT cases are familial, resulting from adenomas or carcinomas associated with mutations in the tumor suppressor genes MEN1 and CDC73 and the RET proto-oncogene.⁵ Multiple endocrine neoplasia (MEN) syndrome type 1 or 2a is associated with the development of parathyroid adenomas and other endocrine tumors.^1,5 Mutations in the CDC73 gene can lead to parathyroid cancer, familial isolated hyperparathyroidism, and familial hyperparathyroidism-jaw tumor syndrome.⁵ Parathyroid cancer is rare and is linked to a history of radiation to the head and neck.³ Ectopic parathyroid adenomas represent 3% to 4% of all parathyroid adenomas and are often found in the mediastinum.¹²PHPT is the third most common endocrine disorder, with a prevalence of 1 case per 1,000 men and 2 to 3 cases per 1,000 women.⁵ Most women with PHPT are postmenopausal and older than 50.¹ The condition can occur in younger adults but is rare in childhood and adolescence, with an incidence of 2 to 5 cases per 100,000.¹³

PHPT affects multiple organ systems, but the most commonly involved are the renal and musculoskeletal systems (see Table 2). The hypersecretory state causes excessive bone resorption and increased osteoclastic activity, resulting in osteoporosis and increased risk for pathologic fractures of the hip, wrist, and spine. The most common osteoporotic fractures are vertebral compression fractures.¹⁴ Fractures involving the thoracic spine contribute to the development of kyphosis.¹⁵

In the kidney, an increased filtered load of calcium leads to hypercalciuria, precipitation of calcium phosphate in the renal pelvis and collecting ducts, metabolic acidosis, alkaline urine, and hyperphosphaturia. The combination of alkaline urine, hyperphosphaturia, and hypercalciuria leads to the formation of kidney stones.⁶ Nephrolithiasis and alkaline urine predispose patients to recurrent urinary tract infections and subsequent renal impairment.⁶ In addition, hypercalcemia impairs the renal collecting system and decreases its response to antidiuretic hormone, resulting in polyuria.⁶

Secondary ­hyperparathyroidism

In secondary hyperparathyroidism, calcium levels are either normal or low. Normocalcemic hyperparathyroidism is characterized by normal ionized and total calcium levels and elevated PTH levels; it has no known cause.⁶ Secondary hyperparathyroidism occurs when excess PTH is excreted as a result of a chronic condition that leads to hypocalcemia. Examples of these disease states include vitamin D deficiency, chronic kidney disease (CKD), and intestinal malabsorption. The most common cause of secondary hyperparathyroidism is CKD; glomerular filtration insufficiency results in hyperphosphatemia, hypocalcemia, and low 1,25(OH)₂D, stimulating the release of PTH. Other causes include deficient intake or decreased absorption of calcium or vitamin D; chronic use of medications such as lithium, phenobarbital, or phenytoin; bariatric surgery; celiac disease; and pancreatic disease.^4,6,14 Lithium decreases urinary calcium excretion and reduces the sensitivity of the parathyroid gland to calcium.⁴

Tertiary hyperparathyroidism

Tertiary hyperparathyroidism, marked by hypercalcemia and excessive PTH secretion, can occur after prolonged secondary hyperparathyroidism. In this disorder, persistent parathyroid stimulation leads to gland hyperplasia, resulting in autonomous production of PTH despite correction of calcium levels.⁶ It most commonly occurs in patients with chronic secondary hyperparathyroidism with renal failure who receive a kidney transplant.^2,6 In some cases, parathyroid hyperplasia may not regress after transplantation and parathyroidectomy may be necessary.

EVALUATION AND DIAGNOSTIC WORK-UP

Laboratory tests

Hypercalcemia is the most common initial finding that leads to the diagnosis of PHPT. Elevated serum calcium and PTH is characteristic of the condition. When evaluating a patient with hypercalcemia, the diagnostic work-up includes tests to differentiate between PTH- and non–PTH-mediated causes of elevated calcium (see Table 3).⁷ Evaluation should begin with measurement of PTH by second- or third-generation immunoassay along with phosphorus, alkaline phosphatase, 25(OH)D, creatinine, estimated glomerular filtration rate (eGFR), and albumin. Additionally, a 24-hour urine collection for calcium, creatinine, and creatinine clearance should be considered in patients with overt nephrolithiasis or nephrocalcinosis. If the urine calcium is > 400 mg/24 h, a renal stone risk profile is indicated because nephrolithiasis is one of the most common complications of PHPT.¹⁴ There is a high prevalence of nephrolithiasis in patients with normocalcemic PHPT, even after parathyroidectomy.¹⁶ If the 24-hour urine calcium level is low, the diagnosis of FHH is considered. If the urine calcium is high and the intact PTH is elevated or inappropriately normal, the diagnosis of PHPT is considered; urine calcium will be normal in 60% of PHPT cases.^4,11

Imaging studies

Imaging is useful for localization of adenomas and abnormal parathyroid tissue to guide surgical planning but is not necessary for diagnosis or medical management. Understanding the strengths and weaknesses of imaging modalities enables the clinician to order the most appropriate option. There are three primary imaging modalities used to locate parathyroid adenoma(s) or aberrant parathyroid tissue: ultrasound, nuclear medicine sestamibi parathyroid scans, and CT. Some clinicians start with an ultrasound, but its operator-dependent results can vary widely; in addition, ultrasound often provides poor anatomic definition and has limited value in locating ectopic parathyroid tissue.¹⁷

Nuclear medicine parathyroid scan with technetium-99m sestamibi is a sensitive method for localizing hyperfunctioning, enlarged parathyroid glands or tissue in normal anatomic positions or ectopic locations. Uptake is enhanced and prolonged in parathyroid adenomas as well as in aberrant tissue found in the mediastinum or subclavicular areas. Sestamibi parathyroid scan detects up to 89% of single adenomas, but studies of this imaging modality have demonstrated a wide range of sensitivities (44%-95%).^5,17 A drawback of nuclear medicine studies is that they provide little anatomic detail.¹⁷ Nonetheless, the ability of the parathyroid scan to locate parathyroid glands has contributed to the success of the minimally invasive parathyroidectomy, and it is considered the most successful imaging modality available.^5,10 Identifying the precise location of the parathyroid adenoma is essential for a successful surgical outcome; this is best achieved by combining the sestamibi parathyroid scan with CT.¹²

Emerging imaging modalities are the multidetector CT (MDCT) and 4D-CT techniques. In an evaluation of the diagnostic accuracy of contrast-enhanced MDCT in the detection of parathyroid adenomas and aberrant parathyroid tissue, MDCT demonstrated the ability to differentiate between adenomas and hyperplasia and display important anatomic structures such as nerves and blood vessels.¹⁷ The specificity of MDCT for ruling out abnormal parathyroid tissue was 75%, and the sensitivity for detecting a single adenoma was 80%. Overall, MDCT demonstrated an 88% positive predictive value (PPV) in localizing hyperfunctioning parathyroid glands but showed poor sensitivity in detecting multigland disease.¹⁷ The PPV is a key value in determining the ability of an imaging study to precisely locate aberrant parathyroid tissue. MDCT provides detailed definition of anatomy, locating ectopic parathyroid glands in the deeper paraesophageal areas and mediastinum while defining relationships between the tissue and its surrounding vasculature, lymph nodes, and thyroid tissue.¹⁷ The 4D-CT technique employs three-dimensional technology and accounts for the movement of the patient’s body over time (the “fourth dimension”). It is an accurate method for identifying parathyroid adenomas but exposes the patient to higher radiation doses.¹⁸ The sensitivity of 4D-CT in localizing abnormal parathyroid tissue is comparable to that of MDCT.^16,18,19

Additional studies used during the management of the patient with PHPT are BMD testing and renal imaging. Secondary causes of bone loss are responsible for up to 30% of osteoporosis cases in postmenopausal women; one of these causes is PHPT.²⁰ Elevated PTH causes increased bone turnover and results in decreased bone mass with subsequent increased fracture risk.⁹ Bone density should be measured by dual-energy x-ray absorptiometry (DEXA), and the skeletal survey should include the distal one-third of the radius, hip, and lumbar spine. The distal radius is rich in cortical bone and BMD is often lowest at this site in patients with PHPT, making it the most sensitive DEXA marker for early detection of bone loss.^19,21 The hip contains an equal mix of cortical and trabecular bone and is the second most sensitive site for detecting bone loss in PHPT. The spine contains a high proportion of trabecular bone and is the least sensitive site.^19,21 Renal imaging studies, including x-ray, ultrasound, and, less frequently, CT of the abdomen and pelvis, are used to assess for nephrolithiasis and nephrocalcinosis.¹⁹

TREATMENT/MANAGEMENT

Conservative medical management

PHPT is a complex disease process, and careful evaluation is required when determining whether medical versus surgical management is appropriate. Clinical presentation ranges from no symptoms to multisystem disease. Conservative medical management, which includes regular monitoring, is an acceptable strategy in an asymptomatic patient with a low fracture risk and no nephrolithiasis.¹ Conservative care includes maintaining normal dietary calcium intake and adequate hydration, regular exercise, vitamin D supplementation, annual laboratory studies, BMD testing, and the avoidance of thiazide diuretics and lithium.¹ Guidelines, from the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism, for monitoring asymptomatic PHPT patients recommend

1. Annual measurement of serum calcium
2. BMD measurement by DEXA every 1 to 2 years
3. Annual assessment of eGFR and serum creatinine
4. Renal imaging or a 24-h urine stone profile if nephrolithiasis is suspected.¹⁹

Long-term medical management of PHPT is difficult because no agents are available to suppress hypercalcemia or completely block PTH release.¹²

Maintaining serum 25(OH)D at a level > 20 ng/mL significantly reduces PTH secretion, in comparison to levels < 20 ng/mL, and does not aggravate hypercalcemia.²² The Endocrine Society recommends a minimum serum 25(OH)D level of 20 ng/mL and notes that targeting a higher threshold value of 30 ng/mL is reasonable.¹⁹ The daily requirement for vitamin D3, 800 IU to 1,000 IU, is a good starting point for supplementation.⁴ Measurement of 1,25(OH)₂D levels lacks value and is not recommended for patients with PHPT. Calcium intake should follow established guidelines and is not limited in PHPT.¹⁹

Surgical management

Surgical management is indicated for symptomatic patients.²³ Indications include nephrolithiasis, nephrocalcinosis, osteitis fibrosa cystica, or osteoporosis. Surgery is considered appropriate for individuals who do not meet these criteria if there are no medical contraindications.¹⁴ The Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism revised the indications for surgery in 2014 to include asymptomatic patients, since surgery is the only definitive treatment for PHPT. Current guidelines for when to recommend surgery in the asymptomatic patient with PHPT are listed in Table 4.¹⁹

Preoperative localization and referral to an experienced surgeon is of utmost importance for a good outcome. An expert surgeon will usually perform a minimally invasive parathyroidectomy (MIP) and obtain intraoperative PTH levels; in some cases, a full neck exploration is necessary. PTH has a half-life of less than five minutes and is an accurate tool for determining whether the culprit gland has been successfully removed.⁵

Modern imaging studies, less invasive surgical techniques, and intraoperative measurements of PTH have decreased the need to conduct full neck exploration. MIP offers a smaller incision, less tissue dissection, and lower morbidity, and can be offered without the risks associated with general anesthesia.¹⁰ The goal of surgery is to restore normocalcemia and, in turn, prevent bone mineral loss and systemic effects of hypercalcemia over the long term.¹⁰ Surgical management for an ectopic parathyroid adenoma is controversial because these are often found in the mediastinum, requiring invasive surgery.¹²

Surgery is curative in up to 95% of cases and has a low rate of complications.^2,24 A joint decision regarding treatment options is made among the patient, primary care clinician, and surgeon. Complications include vocal cord paralysis resulting from injury to the recurrent laryngeal nerve, bleeding or hematoma, laryngospasm, symptomatic hypocalcemia, and persistent hyperparathyroidism; seizures are very rare but can occur from transient hypocalcemia and hypomagnesemia.⁵ PTH levels drop by more than 50% intraoperatively if the procedure is successful; otherwise, exploration for another adenoma is indicated.¹⁰ Postoperative calcium and vitamin D supplementation are warranted once lab values are stable.

When surgery is contraindicated/refused

If surgery is indicated but the patient is a poor candidate or refuses surgery, management of hypercalcemia and bone loss with pharmacologic agents is warranted. The calcimimetic cinacalcet is a reasonable medical alternative that has been shown to adequately control hypercalcemia and hypophosphatemia and has proven effective in various patient subgroups.²⁵ This agent is useful in the treatment of patients who are asymptomatic and refuse surgery, patients with refractory PHPT after parathyroidectomy, and patients with contraindications to surgery.^24,25 The medication reduces calcium and modestly reduces PTH levels by binding parathyroid calcium-sensing receptors but does not improve bone density.^2,12 Cinacalcet is approved by the FDA for use in patients with moderate to severe disease when surgery is contraindicated.²⁴

Treatment options for osteoporosis, vertebral fractures, and progressive bone loss in the patient with PHPT include bisphosphonates. Raloxifene and estrogen replacements may be used in postmenopausal women. Oral bisphosphonates (alendronate or risedronate) are firstline therapies and have been shown to inhibit progression to osteoporosis in PHPT.^9,26 They prevent osteoclastic activity, reducing bone resorption and turnover. Contraindications to oral bisphosphonates include esophageal disorders, gastrointestinal intolerance, or inability to follow the dosing requirements. Intravenous zoledronic acid provides an alternative route of administration.

Alendronate has the best evidence for improving bone density and preventing progression to osteoporosis in patients with PHPT, but the medication does not affect calcium or PTH levels.^1,19 There is limited data on the effects of combining bisphosphonates with calcimimetics. Raloxifene is a selective estrogen receptor modulator that decreases bone resorption; it is approved for treating osteoporosis and may be used when a patient is not a good candidate for a bisphosphonate.²⁰ Denosumab, currently under study for the treatment of PHPT, is a human monoclonal antibody that improves bone density but does not affect serum calcium.²⁰ Nonpharmacologic therapies include alcohol moderation, decreased caffeine intake, weight-bearing exercise, smoking cessation, adequate hydration, and dietary modifications.²⁰

OUTCOME FOR THE CASE PATIENT

Although PHPT is often discovered incidentally in routine blood work with hypercalcemia, the case patient had developed osteoporosis and a grade IV tibial stress fracture before the diagnosis was made. Following parathyroidectomy, her hypertension worsened, requiring an additional antihypertensive medication. She developed recurrent disease and was referred to a tertiary care center for revision parathyroidectomy due to persistent elevated calcium levels. A 24-hour urine calcium test ruled out concurrent FHH. A full neck exploration was conducted and a 340-mg hypercellular parathyroid gland was removed from the left superior pole. She will be monitored for recurrent disease and will remain on a vitamin D3 supplement and treatment for osteoporosis.

CONCLUSION

Primary care clinicians should have a low threshold for initiating the work-up of mild hypercalcemia in an effort to prevent sequelae. Patient education is essential throughout the process. Understanding the condition and treatment options is necessary for a patient’s active participation in clinical decision making. Conservative management of an asymptomatic patient includes avoiding thiazide diuretics and lithium, staying well hydrated with water, maintaining moderate dietary calcium (1,000-1,200 mg/d) and vitamin D (400-600 IU/d) intake, regular exercise, and appropriate lab and bone density monitoring. Surgical treatment is recommended for symptomatic patients exhibiting decreased bone density, fractures, renal impairment, or nephrolithiasis. Treating bone loss with bisphosphonates and hypercalcemia with calcimimetics is useful. Postmenopausal women may benefit from estrogen therapy or selective estrogen receptor modulators. These agents improve bone density and lower calcium, but are often contraindicated or have adverse effects. Surgery is the only cure.³

CE/CME No: CR-1705

PROGRAM OVERVIEW
Earn credit by reading this article and successfully completing the posttest and evaluation. Successful completion is defined as a cumulative score of at least 70% correct.

EDUCATIONAL OBJECTIVES
• Differentiate primary hyperparathyroidism (PHPT) from other causes of hypercalcemia and types of hyerparathyroidism.
• Understand the calcium-parathyroid hormone feedback loop.
• Identify appropriate imaging studies and common laboratory findings in the patient with PHPT.
• Describe the common systemic manifestations of PHPT.
• Discuss medical versus surgical management of the patient with PHPT.

FACULTY
Barbara Austin is a Family Nurse Practitioner at Baptist Primary Care, Jacksonville, Florida, and is pursuing a Doctorate of Nursing Practice (DNP) at Jacksonville University.

The author has no financial relationships to disclose.

ACCREDITATION STATEMENT

This program has been reviewed and is approved for a maximum of 1.0 hour of American Academy of Physician Assistants (AAPA) Category 1 CME credit by the Physician Assistant Review Panel. [NPs: Both ANCC and the AANP Certification Program recognize AAPA as an approved provider of Category 1 credit.] Approval is valid for one year from the issue date of May 2017.

Article begins on next page >>

Primary hyperparathyroidism (PHPT) is most often detected as hypercalcemia in an asymptomatic patient during routine blood work. Knowing the appropriate work-up of hypercalcemia is essential, since untreated PHPT can have significant complications affecting multiple organ systems—most notably, renal and musculoskeletal. Parathyroidectomy is curative in up to 95% of cases, but prevention of long-term complications relies on prompt recognition and appropriate follow-up.

Primary hyperparathyroidism (PHPT) is a common endocrine disorder, with a prevalence of approximately 1 to 3 cases per 1,000 persons.¹ PHPT results from inappropriate overproduction of parathyroid hormone (PTH), the primary regulator of calcium homeostasis, and is characterized by hypercalcemia in the setting of an elevated or high-normal PTH level. In most cases of PHPT, unregulated PTH production is caused by a single parathyroid adenoma.

PHPT is the most common cause of hypercalcemia in outpatients and is typically diagnosed following incidental discovery during routine blood work in an asymptomatic patient.^1,2 It is two to three times more common in women than in men, and incidence increases with age; as such, postmenopausal women are most commonly affected.^1,3 PHPT often has an insidious course, and recognition of its clinical manifestations followed by appropriate diagnostic work-up and management are necessary to prevent sequelae.³

PATIENT PRESENTATION

A 68-year-old Caucasian woman presented to her family practice office for a third visit with continued complaints of nontraumatic right lower leg pain. She had previously been diagnosed with tendonitis, which was treated conservatively. The pain failed to improve, and an x-ray was ordered. The x-ray revealed no acute findings but did show osteopenia, prompting an order for a bone mineral density (BMD) test. The BMD test demonstrated osteoporosis, which warranted further investigation. She was prescribed alendronate but refused it, against medical advice, due to concern over potential adverse effects.

Her medical history included hyperlipidemia and hypertension under fair control with lisinopril. She took a low-dose aspirin and flaxseed supplement daily. She also had a history of radiation to the neck, having undergone tonsillar irradiation as a child (a common practice from the 1930s through the 1950s).³ Surgical history included a total hysterectomy with bilateral salpingo-oophorectomy, appendectomy, and tonsillectomy. There was no personal or family history of cancer or endocrine disorders, hypercalcemia, or nephrolithiasis. She was up to date on vaccines and preventive health care measures. Allergies included penicillin and sulfa, both resulting in hives. She was a nonsmoker and did not drink alcohol or engage in illicit drug use.

Review of systems revealed right lower anterior leg pain for four months, characterized as aching, deep, sharp, and throbbing with radiation to the ankle. The pain was worse with activity and prolonged standing; ibuprofen and application of ice provided partial relief. She had experienced some mood changes, including irritability. Physical exam was normal except for dominant right-sided thyromegaly, marked bony point tenderness to the right midshin area, and an antalgic gait.

Laboratory work-up demonstrated elevated PTH, alkaline phosphatase, and calcium levels and a low 25-hydroxyvitamin D [25(OH)D] level (see Table 1). MRI of the right lower leg revealed a grade IV stress fracture (see Figure 1). The elevated serum calcium and PTH levels in addition to abnormal bone density findings led to the diagnosis of PHPT. She was referred to endocrinology and orthopedics for management of PHPT and the stress fracture, respectively, and was placed in an orthopedic walking boot for treatment of the midtibial stress fracture.

The endocrinologist referred her to an otolaryngologist trained in the surgical management of parathyroid adenomas, who ordered a thyroid ultrasound; this study was inconclusive. Additional imaging, including a Tc-99m sestamibi parathyroid scan and CT with contrast of the soft tissue of the neck, was obtained. The parathyroid scan of the neck and upper chest showed retained activity in the right inferior thyroid pole that was concerning for a parathyroid adenoma (see Figure 2). The CT identified a 1.5-cm parathyroid adenoma off the right inferior pole of the thyroid gland (concordant with the parathyroid scan). A single 300-mg parathyroid adenoma was removed from the right inferior pole of the thyroid. The surgery was deemed successful, with intraoperative normalization of the PTH level.

The patient was managed postoperatively by the endocrinologist and was started on calcium and vitamin D supplements. She was prescribed a bisphosphonate, as she had refused to take alendronate following her abnormal BMD test.

DIFFERENTIAL DIAGNOSIS

PHPT and malignancy are the most common causes of hypercalcemia, accounting for 90% of cases.^2,4 A less common cause is familial hypocalciuric hypercalcemia (FHH), a rare benign disorder that imitates PHPT.¹ FHH is ruled out by measurement of 24-hour urine calcium excretion and is characterized by hypocalciuria, defined as a urine calcium level of less than 100 mg/24 h (reference range, 100-300 mg/24 h).² Low calcium excretion can also be identified by a calcium-creatinine excretion ratio.² FHH is a benign autosomal dominant condition caused by a heterozygous mutation of the parathyroid glands’ calcium-sensing receptors.^2,5,6 Young adults with FHH are asymptomatic, and mild hypercalcemia and a normal or slightly elevated PTH are the only laboratory findings.⁴

Measuring PTH levels is key in determining the underlying mechanism of hypercalcemia.^2,7 If the hypercalcemia is not PTH-mediated, malignancy and granulomatous diseases such as sarcoidosis must be considered.^2,7 PTH is suppressed in malignancy except for rare cases of PTH-producing tumors.⁴ Bone metastases cause calcium resorption, and sarcoidosis causes an excess of vitamin D, both resulting in hypercalcemia. Lymphomas and sarcoid granulomas express 1α-hydroxylase, an enzyme that increases the conversion of 25(OH)D to 1,25-dihydroxyvitamin D [1,25(OH)₂D].² When malignancy is suspected, it is appropriate to check a 1,25(OH)₂D level. Thiazide diuretics, such as hydrochlorothiazide, decrease urinary calcium excretion and may result in mild hypercalcemia.² Other possibilities in the differential include hypervitaminosis A or D, dehydration, and excess calcium ingestion, but these are less common.^6,7

CALCIUM REGULATION

The parathyroid glands stem from four poles on the back of the thyroid gland; there are typically four, but the number can vary from two to 11. Secreted PTH, the primary regulator of calcium homeostasis, maintains calcium levels within a narrow physiologic range.^2,8 PTH increases bone resorption, stimulating release of calcium into the blood, and signals the kidneys to increase reabsorption of calcium and excrete phosphorus. It also converts 25(OH)D to 1,25(OH)₂ D, the active form of vitamin D that increases gastrointestinal calcium absorption. In a negative feedback loop, PTH secretion is regulated by serum calcium levels, stimulated when levels are low and suppressed when levels are high (see Figure 3).³ Calcium-sensing receptors, located in the chief cells of parathyroid tissue, are essential to calcium homeostasis. These receptors will either increase or decrease PTH release in response to small changes in blood ionized calcium levels. The receptors also play an independent role in the renal tubules by promoting secretion of calcium in the setting of hypercalcemia.^5,9 The precise regulation of intracellular and extracellular calcium is necessary for normal functioning of physiologic processes, including bone metabolism, hormone release and regulation, neuromuscular function, and cell signaling.⁵

PATHOPHYSIOLOGY

Hyperparathyroidism is defined as excess secretion of PTH and is categorized as primary, secondary, or tertiary based on pathophysiologic mechanisms.

Primary hyperparathyroidism

PHPT is defined as PTH levels that are elevated or inappropriately normal in patients with hypercalcemia and no known history of kidney disease.^2,6 This occurs when the normal feedback mechanism fails to inhibit excess hormone secretion by one or more of the parathyroid glands.⁶ With uninhibited PTH secretion, hypercalcemia will result from increased gastrointestinal absorption and bone resorption.

The most common causes of PHPT are an abnormal proliferation of parathyroid cells (parathyroid adenomas) and parathyroid tissue overgrowth (hyperplasia). PHPT may result from a single parathyroid adenoma (80%-90%), multigland hyperplasia (10%-15%), multiple adenomas (2%-3%), or malignancy (< 1%).^6,10 Adenomas can occur sporadically or less commonly as part of an inherited syndrome.¹ It is estimated that more than 10% of patients with PHPT have a mutation in one of 11 genes associated with PHPT.¹¹ Approximately 5% of PHPT cases are familial, resulting from adenomas or carcinomas associated with mutations in the tumor suppressor genes MEN1 and CDC73 and the RET proto-oncogene.⁵ Multiple endocrine neoplasia (MEN) syndrome type 1 or 2a is associated with the development of parathyroid adenomas and other endocrine tumors.^1,5 Mutations in the CDC73 gene can lead to parathyroid cancer, familial isolated hyperparathyroidism, and familial hyperparathyroidism-jaw tumor syndrome.⁵ Parathyroid cancer is rare and is linked to a history of radiation to the head and neck.³ Ectopic parathyroid adenomas represent 3% to 4% of all parathyroid adenomas and are often found in the mediastinum.¹²PHPT is the third most common endocrine disorder, with a prevalence of 1 case per 1,000 men and 2 to 3 cases per 1,000 women.⁵ Most women with PHPT are postmenopausal and older than 50.¹ The condition can occur in younger adults but is rare in childhood and adolescence, with an incidence of 2 to 5 cases per 100,000.¹³

PHPT affects multiple organ systems, but the most commonly involved are the renal and musculoskeletal systems (see Table 2). The hypersecretory state causes excessive bone resorption and increased osteoclastic activity, resulting in osteoporosis and increased risk for pathologic fractures of the hip, wrist, and spine. The most common osteoporotic fractures are vertebral compression fractures.¹⁴ Fractures involving the thoracic spine contribute to the development of kyphosis.¹⁵

In the kidney, an increased filtered load of calcium leads to hypercalciuria, precipitation of calcium phosphate in the renal pelvis and collecting ducts, metabolic acidosis, alkaline urine, and hyperphosphaturia. The combination of alkaline urine, hyperphosphaturia, and hypercalciuria leads to the formation of kidney stones.⁶ Nephrolithiasis and alkaline urine predispose patients to recurrent urinary tract infections and subsequent renal impairment.⁶ In addition, hypercalcemia impairs the renal collecting system and decreases its response to antidiuretic hormone, resulting in polyuria.⁶

Secondary ­hyperparathyroidism

In secondary hyperparathyroidism, calcium levels are either normal or low. Normocalcemic hyperparathyroidism is characterized by normal ionized and total calcium levels and elevated PTH levels; it has no known cause.⁶ Secondary hyperparathyroidism occurs when excess PTH is excreted as a result of a chronic condition that leads to hypocalcemia. Examples of these disease states include vitamin D deficiency, chronic kidney disease (CKD), and intestinal malabsorption. The most common cause of secondary hyperparathyroidism is CKD; glomerular filtration insufficiency results in hyperphosphatemia, hypocalcemia, and low 1,25(OH)₂D, stimulating the release of PTH. Other causes include deficient intake or decreased absorption of calcium or vitamin D; chronic use of medications such as lithium, phenobarbital, or phenytoin; bariatric surgery; celiac disease; and pancreatic disease.^4,6,14 Lithium decreases urinary calcium excretion and reduces the sensitivity of the parathyroid gland to calcium.⁴

Tertiary hyperparathyroidism

Tertiary hyperparathyroidism, marked by hypercalcemia and excessive PTH secretion, can occur after prolonged secondary hyperparathyroidism. In this disorder, persistent parathyroid stimulation leads to gland hyperplasia, resulting in autonomous production of PTH despite correction of calcium levels.⁶ It most commonly occurs in patients with chronic secondary hyperparathyroidism with renal failure who receive a kidney transplant.^2,6 In some cases, parathyroid hyperplasia may not regress after transplantation and parathyroidectomy may be necessary.

EVALUATION AND DIAGNOSTIC WORK-UP

Laboratory tests

Hypercalcemia is the most common initial finding that leads to the diagnosis of PHPT. Elevated serum calcium and PTH is characteristic of the condition. When evaluating a patient with hypercalcemia, the diagnostic work-up includes tests to differentiate between PTH- and non–PTH-mediated causes of elevated calcium (see Table 3).⁷ Evaluation should begin with measurement of PTH by second- or third-generation immunoassay along with phosphorus, alkaline phosphatase, 25(OH)D, creatinine, estimated glomerular filtration rate (eGFR), and albumin. Additionally, a 24-hour urine collection for calcium, creatinine, and creatinine clearance should be considered in patients with overt nephrolithiasis or nephrocalcinosis. If the urine calcium is > 400 mg/24 h, a renal stone risk profile is indicated because nephrolithiasis is one of the most common complications of PHPT.¹⁴ There is a high prevalence of nephrolithiasis in patients with normocalcemic PHPT, even after parathyroidectomy.¹⁶ If the 24-hour urine calcium level is low, the diagnosis of FHH is considered. If the urine calcium is high and the intact PTH is elevated or inappropriately normal, the diagnosis of PHPT is considered; urine calcium will be normal in 60% of PHPT cases.^4,11

Imaging studies

Imaging is useful for localization of adenomas and abnormal parathyroid tissue to guide surgical planning but is not necessary for diagnosis or medical management. Understanding the strengths and weaknesses of imaging modalities enables the clinician to order the most appropriate option. There are three primary imaging modalities used to locate parathyroid adenoma(s) or aberrant parathyroid tissue: ultrasound, nuclear medicine sestamibi parathyroid scans, and CT. Some clinicians start with an ultrasound, but its operator-dependent results can vary widely; in addition, ultrasound often provides poor anatomic definition and has limited value in locating ectopic parathyroid tissue.¹⁷

Nuclear medicine parathyroid scan with technetium-99m sestamibi is a sensitive method for localizing hyperfunctioning, enlarged parathyroid glands or tissue in normal anatomic positions or ectopic locations. Uptake is enhanced and prolonged in parathyroid adenomas as well as in aberrant tissue found in the mediastinum or subclavicular areas. Sestamibi parathyroid scan detects up to 89% of single adenomas, but studies of this imaging modality have demonstrated a wide range of sensitivities (44%-95%).^5,17 A drawback of nuclear medicine studies is that they provide little anatomic detail.¹⁷ Nonetheless, the ability of the parathyroid scan to locate parathyroid glands has contributed to the success of the minimally invasive parathyroidectomy, and it is considered the most successful imaging modality available.^5,10 Identifying the precise location of the parathyroid adenoma is essential for a successful surgical outcome; this is best achieved by combining the sestamibi parathyroid scan with CT.¹²

Emerging imaging modalities are the multidetector CT (MDCT) and 4D-CT techniques. In an evaluation of the diagnostic accuracy of contrast-enhanced MDCT in the detection of parathyroid adenomas and aberrant parathyroid tissue, MDCT demonstrated the ability to differentiate between adenomas and hyperplasia and display important anatomic structures such as nerves and blood vessels.¹⁷ The specificity of MDCT for ruling out abnormal parathyroid tissue was 75%, and the sensitivity for detecting a single adenoma was 80%. Overall, MDCT demonstrated an 88% positive predictive value (PPV) in localizing hyperfunctioning parathyroid glands but showed poor sensitivity in detecting multigland disease.¹⁷ The PPV is a key value in determining the ability of an imaging study to precisely locate aberrant parathyroid tissue. MDCT provides detailed definition of anatomy, locating ectopic parathyroid glands in the deeper paraesophageal areas and mediastinum while defining relationships between the tissue and its surrounding vasculature, lymph nodes, and thyroid tissue.¹⁷ The 4D-CT technique employs three-dimensional technology and accounts for the movement of the patient’s body over time (the “fourth dimension”). It is an accurate method for identifying parathyroid adenomas but exposes the patient to higher radiation doses.¹⁸ The sensitivity of 4D-CT in localizing abnormal parathyroid tissue is comparable to that of MDCT.^16,18,19

Additional studies used during the management of the patient with PHPT are BMD testing and renal imaging. Secondary causes of bone loss are responsible for up to 30% of osteoporosis cases in postmenopausal women; one of these causes is PHPT.²⁰ Elevated PTH causes increased bone turnover and results in decreased bone mass with subsequent increased fracture risk.⁹ Bone density should be measured by dual-energy x-ray absorptiometry (DEXA), and the skeletal survey should include the distal one-third of the radius, hip, and lumbar spine. The distal radius is rich in cortical bone and BMD is often lowest at this site in patients with PHPT, making it the most sensitive DEXA marker for early detection of bone loss.^19,21 The hip contains an equal mix of cortical and trabecular bone and is the second most sensitive site for detecting bone loss in PHPT. The spine contains a high proportion of trabecular bone and is the least sensitive site.^19,21 Renal imaging studies, including x-ray, ultrasound, and, less frequently, CT of the abdomen and pelvis, are used to assess for nephrolithiasis and nephrocalcinosis.¹⁹

TREATMENT/MANAGEMENT

Conservative medical management

PHPT is a complex disease process, and careful evaluation is required when determining whether medical versus surgical management is appropriate. Clinical presentation ranges from no symptoms to multisystem disease. Conservative medical management, which includes regular monitoring, is an acceptable strategy in an asymptomatic patient with a low fracture risk and no nephrolithiasis.¹ Conservative care includes maintaining normal dietary calcium intake and adequate hydration, regular exercise, vitamin D supplementation, annual laboratory studies, BMD testing, and the avoidance of thiazide diuretics and lithium.¹ Guidelines, from the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism, for monitoring asymptomatic PHPT patients recommend

1. Annual measurement of serum calcium
2. BMD measurement by DEXA every 1 to 2 years
3. Annual assessment of eGFR and serum creatinine
4. Renal imaging or a 24-h urine stone profile if nephrolithiasis is suspected.¹⁹

Long-term medical management of PHPT is difficult because no agents are available to suppress hypercalcemia or completely block PTH release.¹²

Maintaining serum 25(OH)D at a level > 20 ng/mL significantly reduces PTH secretion, in comparison to levels < 20 ng/mL, and does not aggravate hypercalcemia.²² The Endocrine Society recommends a minimum serum 25(OH)D level of 20 ng/mL and notes that targeting a higher threshold value of 30 ng/mL is reasonable.¹⁹ The daily requirement for vitamin D3, 800 IU to 1,000 IU, is a good starting point for supplementation.⁴ Measurement of 1,25(OH)₂D levels lacks value and is not recommended for patients with PHPT. Calcium intake should follow established guidelines and is not limited in PHPT.¹⁹

Surgical management

Surgical management is indicated for symptomatic patients.²³ Indications include nephrolithiasis, nephrocalcinosis, osteitis fibrosa cystica, or osteoporosis. Surgery is considered appropriate for individuals who do not meet these criteria if there are no medical contraindications.¹⁴ The Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism revised the indications for surgery in 2014 to include asymptomatic patients, since surgery is the only definitive treatment for PHPT. Current guidelines for when to recommend surgery in the asymptomatic patient with PHPT are listed in Table 4.¹⁹

Preoperative localization and referral to an experienced surgeon is of utmost importance for a good outcome. An expert surgeon will usually perform a minimally invasive parathyroidectomy (MIP) and obtain intraoperative PTH levels; in some cases, a full neck exploration is necessary. PTH has a half-life of less than five minutes and is an accurate tool for determining whether the culprit gland has been successfully removed.⁵

Modern imaging studies, less invasive surgical techniques, and intraoperative measurements of PTH have decreased the need to conduct full neck exploration. MIP offers a smaller incision, less tissue dissection, and lower morbidity, and can be offered without the risks associated with general anesthesia.¹⁰ The goal of surgery is to restore normocalcemia and, in turn, prevent bone mineral loss and systemic effects of hypercalcemia over the long term.¹⁰ Surgical management for an ectopic parathyroid adenoma is controversial because these are often found in the mediastinum, requiring invasive surgery.¹²

Surgery is curative in up to 95% of cases and has a low rate of complications.^2,24 A joint decision regarding treatment options is made among the patient, primary care clinician, and surgeon. Complications include vocal cord paralysis resulting from injury to the recurrent laryngeal nerve, bleeding or hematoma, laryngospasm, symptomatic hypocalcemia, and persistent hyperparathyroidism; seizures are very rare but can occur from transient hypocalcemia and hypomagnesemia.⁵ PTH levels drop by more than 50% intraoperatively if the procedure is successful; otherwise, exploration for another adenoma is indicated.¹⁰ Postoperative calcium and vitamin D supplementation are warranted once lab values are stable.

When surgery is contraindicated/refused

If surgery is indicated but the patient is a poor candidate or refuses surgery, management of hypercalcemia and bone loss with pharmacologic agents is warranted. The calcimimetic cinacalcet is a reasonable medical alternative that has been shown to adequately control hypercalcemia and hypophosphatemia and has proven effective in various patient subgroups.²⁵ This agent is useful in the treatment of patients who are asymptomatic and refuse surgery, patients with refractory PHPT after parathyroidectomy, and patients with contraindications to surgery.^24,25 The medication reduces calcium and modestly reduces PTH levels by binding parathyroid calcium-sensing receptors but does not improve bone density.^2,12 Cinacalcet is approved by the FDA for use in patients with moderate to severe disease when surgery is contraindicated.²⁴

Treatment options for osteoporosis, vertebral fractures, and progressive bone loss in the patient with PHPT include bisphosphonates. Raloxifene and estrogen replacements may be used in postmenopausal women. Oral bisphosphonates (alendronate or risedronate) are firstline therapies and have been shown to inhibit progression to osteoporosis in PHPT.^9,26 They prevent osteoclastic activity, reducing bone resorption and turnover. Contraindications to oral bisphosphonates include esophageal disorders, gastrointestinal intolerance, or inability to follow the dosing requirements. Intravenous zoledronic acid provides an alternative route of administration.

Alendronate has the best evidence for improving bone density and preventing progression to osteoporosis in patients with PHPT, but the medication does not affect calcium or PTH levels.^1,19 There is limited data on the effects of combining bisphosphonates with calcimimetics. Raloxifene is a selective estrogen receptor modulator that decreases bone resorption; it is approved for treating osteoporosis and may be used when a patient is not a good candidate for a bisphosphonate.²⁰ Denosumab, currently under study for the treatment of PHPT, is a human monoclonal antibody that improves bone density but does not affect serum calcium.²⁰ Nonpharmacologic therapies include alcohol moderation, decreased caffeine intake, weight-bearing exercise, smoking cessation, adequate hydration, and dietary modifications.²⁰

OUTCOME FOR THE CASE PATIENT

Although PHPT is often discovered incidentally in routine blood work with hypercalcemia, the case patient had developed osteoporosis and a grade IV tibial stress fracture before the diagnosis was made. Following parathyroidectomy, her hypertension worsened, requiring an additional antihypertensive medication. She developed recurrent disease and was referred to a tertiary care center for revision parathyroidectomy due to persistent elevated calcium levels. A 24-hour urine calcium test ruled out concurrent FHH. A full neck exploration was conducted and a 340-mg hypercellular parathyroid gland was removed from the left superior pole. She will be monitored for recurrent disease and will remain on a vitamin D3 supplement and treatment for osteoporosis.

CONCLUSION

Primary care clinicians should have a low threshold for initiating the work-up of mild hypercalcemia in an effort to prevent sequelae. Patient education is essential throughout the process. Understanding the condition and treatment options is necessary for a patient’s active participation in clinical decision making. Conservative management of an asymptomatic patient includes avoiding thiazide diuretics and lithium, staying well hydrated with water, maintaining moderate dietary calcium (1,000-1,200 mg/d) and vitamin D (400-600 IU/d) intake, regular exercise, and appropriate lab and bone density monitoring. Surgical treatment is recommended for symptomatic patients exhibiting decreased bone density, fractures, renal impairment, or nephrolithiasis. Treating bone loss with bisphosphonates and hypercalcemia with calcimimetics is useful. Postmenopausal women may benefit from estrogen therapy or selective estrogen receptor modulators. These agents improve bone density and lower calcium, but are often contraindicated or have adverse effects. Surgery is the only cure.³

CE/CME No: CR-1705

PROGRAM OVERVIEW
Earn credit by reading this article and successfully completing the posttest and evaluation. Successful completion is defined as a cumulative score of at least 70% correct.

EDUCATIONAL OBJECTIVES
• Differentiate primary hyperparathyroidism (PHPT) from other causes of hypercalcemia and types of hyerparathyroidism.
• Understand the calcium-parathyroid hormone feedback loop.
• Identify appropriate imaging studies and common laboratory findings in the patient with PHPT.
• Describe the common systemic manifestations of PHPT.
• Discuss medical versus surgical management of the patient with PHPT.

FACULTY
Barbara Austin is a Family Nurse Practitioner at Baptist Primary Care, Jacksonville, Florida, and is pursuing a Doctorate of Nursing Practice (DNP) at Jacksonville University.

The author has no financial relationships to disclose.

ACCREDITATION STATEMENT

This program has been reviewed and is approved for a maximum of 1.0 hour of American Academy of Physician Assistants (AAPA) Category 1 CME credit by the Physician Assistant Review Panel. [NPs: Both ANCC and the AANP Certification Program recognize AAPA as an approved provider of Category 1 credit.] Approval is valid for one year from the issue date of May 2017.

Article begins on next page >>

Primary hyperparathyroidism (PHPT) is most often detected as hypercalcemia in an asymptomatic patient during routine blood work. Knowing the appropriate work-up of hypercalcemia is essential, since untreated PHPT can have significant complications affecting multiple organ systems—most notably, renal and musculoskeletal. Parathyroidectomy is curative in up to 95% of cases, but prevention of long-term complications relies on prompt recognition and appropriate follow-up.

Primary hyperparathyroidism (PHPT) is a common endocrine disorder, with a prevalence of approximately 1 to 3 cases per 1,000 persons.¹ PHPT results from inappropriate overproduction of parathyroid hormone (PTH), the primary regulator of calcium homeostasis, and is characterized by hypercalcemia in the setting of an elevated or high-normal PTH level. In most cases of PHPT, unregulated PTH production is caused by a single parathyroid adenoma.

PHPT is the most common cause of hypercalcemia in outpatients and is typically diagnosed following incidental discovery during routine blood work in an asymptomatic patient.^1,2 It is two to three times more common in women than in men, and incidence increases with age; as such, postmenopausal women are most commonly affected.^1,3 PHPT often has an insidious course, and recognition of its clinical manifestations followed by appropriate diagnostic work-up and management are necessary to prevent sequelae.³

PATIENT PRESENTATION

A 68-year-old Caucasian woman presented to her family practice office for a third visit with continued complaints of nontraumatic right lower leg pain. She had previously been diagnosed with tendonitis, which was treated conservatively. The pain failed to improve, and an x-ray was ordered. The x-ray revealed no acute findings but did show osteopenia, prompting an order for a bone mineral density (BMD) test. The BMD test demonstrated osteoporosis, which warranted further investigation. She was prescribed alendronate but refused it, against medical advice, due to concern over potential adverse effects.

Her medical history included hyperlipidemia and hypertension under fair control with lisinopril. She took a low-dose aspirin and flaxseed supplement daily. She also had a history of radiation to the neck, having undergone tonsillar irradiation as a child (a common practice from the 1930s through the 1950s).³ Surgical history included a total hysterectomy with bilateral salpingo-oophorectomy, appendectomy, and tonsillectomy. There was no personal or family history of cancer or endocrine disorders, hypercalcemia, or nephrolithiasis. She was up to date on vaccines and preventive health care measures. Allergies included penicillin and sulfa, both resulting in hives. She was a nonsmoker and did not drink alcohol or engage in illicit drug use.

Review of systems revealed right lower anterior leg pain for four months, characterized as aching, deep, sharp, and throbbing with radiation to the ankle. The pain was worse with activity and prolonged standing; ibuprofen and application of ice provided partial relief. She had experienced some mood changes, including irritability. Physical exam was normal except for dominant right-sided thyromegaly, marked bony point tenderness to the right midshin area, and an antalgic gait.

Laboratory work-up demonstrated elevated PTH, alkaline phosphatase, and calcium levels and a low 25-hydroxyvitamin D [25(OH)D] level (see Table 1). MRI of the right lower leg revealed a grade IV stress fracture (see Figure 1). The elevated serum calcium and PTH levels in addition to abnormal bone density findings led to the diagnosis of PHPT. She was referred to endocrinology and orthopedics for management of PHPT and the stress fracture, respectively, and was placed in an orthopedic walking boot for treatment of the midtibial stress fracture.

The endocrinologist referred her to an otolaryngologist trained in the surgical management of parathyroid adenomas, who ordered a thyroid ultrasound; this study was inconclusive. Additional imaging, including a Tc-99m sestamibi parathyroid scan and CT with contrast of the soft tissue of the neck, was obtained. The parathyroid scan of the neck and upper chest showed retained activity in the right inferior thyroid pole that was concerning for a parathyroid adenoma (see Figure 2). The CT identified a 1.5-cm parathyroid adenoma off the right inferior pole of the thyroid gland (concordant with the parathyroid scan). A single 300-mg parathyroid adenoma was removed from the right inferior pole of the thyroid. The surgery was deemed successful, with intraoperative normalization of the PTH level.

The patient was managed postoperatively by the endocrinologist and was started on calcium and vitamin D supplements. She was prescribed a bisphosphonate, as she had refused to take alendronate following her abnormal BMD test.

DIFFERENTIAL DIAGNOSIS

PHPT and malignancy are the most common causes of hypercalcemia, accounting for 90% of cases.^2,4 A less common cause is familial hypocalciuric hypercalcemia (FHH), a rare benign disorder that imitates PHPT.¹ FHH is ruled out by measurement of 24-hour urine calcium excretion and is characterized by hypocalciuria, defined as a urine calcium level of less than 100 mg/24 h (reference range, 100-300 mg/24 h).² Low calcium excretion can also be identified by a calcium-creatinine excretion ratio.² FHH is a benign autosomal dominant condition caused by a heterozygous mutation of the parathyroid glands’ calcium-sensing receptors.^2,5,6 Young adults with FHH are asymptomatic, and mild hypercalcemia and a normal or slightly elevated PTH are the only laboratory findings.⁴

Measuring PTH levels is key in determining the underlying mechanism of hypercalcemia.^2,7 If the hypercalcemia is not PTH-mediated, malignancy and granulomatous diseases such as sarcoidosis must be considered.^2,7 PTH is suppressed in malignancy except for rare cases of PTH-producing tumors.⁴ Bone metastases cause calcium resorption, and sarcoidosis causes an excess of vitamin D, both resulting in hypercalcemia. Lymphomas and sarcoid granulomas express 1α-hydroxylase, an enzyme that increases the conversion of 25(OH)D to 1,25-dihydroxyvitamin D [1,25(OH)₂D].² When malignancy is suspected, it is appropriate to check a 1,25(OH)₂D level. Thiazide diuretics, such as hydrochlorothiazide, decrease urinary calcium excretion and may result in mild hypercalcemia.² Other possibilities in the differential include hypervitaminosis A or D, dehydration, and excess calcium ingestion, but these are less common.^6,7

CALCIUM REGULATION

The parathyroid glands stem from four poles on the back of the thyroid gland; there are typically four, but the number can vary from two to 11. Secreted PTH, the primary regulator of calcium homeostasis, maintains calcium levels within a narrow physiologic range.^2,8 PTH increases bone resorption, stimulating release of calcium into the blood, and signals the kidneys to increase reabsorption of calcium and excrete phosphorus. It also converts 25(OH)D to 1,25(OH)₂ D, the active form of vitamin D that increases gastrointestinal calcium absorption. In a negative feedback loop, PTH secretion is regulated by serum calcium levels, stimulated when levels are low and suppressed when levels are high (see Figure 3).³ Calcium-sensing receptors, located in the chief cells of parathyroid tissue, are essential to calcium homeostasis. These receptors will either increase or decrease PTH release in response to small changes in blood ionized calcium levels. The receptors also play an independent role in the renal tubules by promoting secretion of calcium in the setting of hypercalcemia.^5,9 The precise regulation of intracellular and extracellular calcium is necessary for normal functioning of physiologic processes, including bone metabolism, hormone release and regulation, neuromuscular function, and cell signaling.⁵

PATHOPHYSIOLOGY

Hyperparathyroidism is defined as excess secretion of PTH and is categorized as primary, secondary, or tertiary based on pathophysiologic mechanisms.

Primary hyperparathyroidism

PHPT is defined as PTH levels that are elevated or inappropriately normal in patients with hypercalcemia and no known history of kidney disease.^2,6 This occurs when the normal feedback mechanism fails to inhibit excess hormone secretion by one or more of the parathyroid glands.⁶ With uninhibited PTH secretion, hypercalcemia will result from increased gastrointestinal absorption and bone resorption.

The most common causes of PHPT are an abnormal proliferation of parathyroid cells (parathyroid adenomas) and parathyroid tissue overgrowth (hyperplasia). PHPT may result from a single parathyroid adenoma (80%-90%), multigland hyperplasia (10%-15%), multiple adenomas (2%-3%), or malignancy (< 1%).^6,10 Adenomas can occur sporadically or less commonly as part of an inherited syndrome.¹ It is estimated that more than 10% of patients with PHPT have a mutation in one of 11 genes associated with PHPT.¹¹ Approximately 5% of PHPT cases are familial, resulting from adenomas or carcinomas associated with mutations in the tumor suppressor genes MEN1 and CDC73 and the RET proto-oncogene.⁵ Multiple endocrine neoplasia (MEN) syndrome type 1 or 2a is associated with the development of parathyroid adenomas and other endocrine tumors.^1,5 Mutations in the CDC73 gene can lead to parathyroid cancer, familial isolated hyperparathyroidism, and familial hyperparathyroidism-jaw tumor syndrome.⁵ Parathyroid cancer is rare and is linked to a history of radiation to the head and neck.³ Ectopic parathyroid adenomas represent 3% to 4% of all parathyroid adenomas and are often found in the mediastinum.¹²PHPT is the third most common endocrine disorder, with a prevalence of 1 case per 1,000 men and 2 to 3 cases per 1,000 women.⁵ Most women with PHPT are postmenopausal and older than 50.¹ The condition can occur in younger adults but is rare in childhood and adolescence, with an incidence of 2 to 5 cases per 100,000.¹³

PHPT affects multiple organ systems, but the most commonly involved are the renal and musculoskeletal systems (see Table 2). The hypersecretory state causes excessive bone resorption and increased osteoclastic activity, resulting in osteoporosis and increased risk for pathologic fractures of the hip, wrist, and spine. The most common osteoporotic fractures are vertebral compression fractures.¹⁴ Fractures involving the thoracic spine contribute to the development of kyphosis.¹⁵

In the kidney, an increased filtered load of calcium leads to hypercalciuria, precipitation of calcium phosphate in the renal pelvis and collecting ducts, metabolic acidosis, alkaline urine, and hyperphosphaturia. The combination of alkaline urine, hyperphosphaturia, and hypercalciuria leads to the formation of kidney stones.⁶ Nephrolithiasis and alkaline urine predispose patients to recurrent urinary tract infections and subsequent renal impairment.⁶ In addition, hypercalcemia impairs the renal collecting system and decreases its response to antidiuretic hormone, resulting in polyuria.⁶

Secondary ­hyperparathyroidism

In secondary hyperparathyroidism, calcium levels are either normal or low. Normocalcemic hyperparathyroidism is characterized by normal ionized and total calcium levels and elevated PTH levels; it has no known cause.⁶ Secondary hyperparathyroidism occurs when excess PTH is excreted as a result of a chronic condition that leads to hypocalcemia. Examples of these disease states include vitamin D deficiency, chronic kidney disease (CKD), and intestinal malabsorption. The most common cause of secondary hyperparathyroidism is CKD; glomerular filtration insufficiency results in hyperphosphatemia, hypocalcemia, and low 1,25(OH)₂D, stimulating the release of PTH. Other causes include deficient intake or decreased absorption of calcium or vitamin D; chronic use of medications such as lithium, phenobarbital, or phenytoin; bariatric surgery; celiac disease; and pancreatic disease.^4,6,14 Lithium decreases urinary calcium excretion and reduces the sensitivity of the parathyroid gland to calcium.⁴

Tertiary hyperparathyroidism

Tertiary hyperparathyroidism, marked by hypercalcemia and excessive PTH secretion, can occur after prolonged secondary hyperparathyroidism. In this disorder, persistent parathyroid stimulation leads to gland hyperplasia, resulting in autonomous production of PTH despite correction of calcium levels.⁶ It most commonly occurs in patients with chronic secondary hyperparathyroidism with renal failure who receive a kidney transplant.^2,6 In some cases, parathyroid hyperplasia may not regress after transplantation and parathyroidectomy may be necessary.

EVALUATION AND DIAGNOSTIC WORK-UP

Laboratory tests

Hypercalcemia is the most common initial finding that leads to the diagnosis of PHPT. Elevated serum calcium and PTH is characteristic of the condition. When evaluating a patient with hypercalcemia, the diagnostic work-up includes tests to differentiate between PTH- and non–PTH-mediated causes of elevated calcium (see Table 3).⁷ Evaluation should begin with measurement of PTH by second- or third-generation immunoassay along with phosphorus, alkaline phosphatase, 25(OH)D, creatinine, estimated glomerular filtration rate (eGFR), and albumin. Additionally, a 24-hour urine collection for calcium, creatinine, and creatinine clearance should be considered in patients with overt nephrolithiasis or nephrocalcinosis. If the urine calcium is > 400 mg/24 h, a renal stone risk profile is indicated because nephrolithiasis is one of the most common complications of PHPT.¹⁴ There is a high prevalence of nephrolithiasis in patients with normocalcemic PHPT, even after parathyroidectomy.¹⁶ If the 24-hour urine calcium level is low, the diagnosis of FHH is considered. If the urine calcium is high and the intact PTH is elevated or inappropriately normal, the diagnosis of PHPT is considered; urine calcium will be normal in 60% of PHPT cases.^4,11

Imaging studies

Imaging is useful for localization of adenomas and abnormal parathyroid tissue to guide surgical planning but is not necessary for diagnosis or medical management. Understanding the strengths and weaknesses of imaging modalities enables the clinician to order the most appropriate option. There are three primary imaging modalities used to locate parathyroid adenoma(s) or aberrant parathyroid tissue: ultrasound, nuclear medicine sestamibi parathyroid scans, and CT. Some clinicians start with an ultrasound, but its operator-dependent results can vary widely; in addition, ultrasound often provides poor anatomic definition and has limited value in locating ectopic parathyroid tissue.¹⁷

Nuclear medicine parathyroid scan with technetium-99m sestamibi is a sensitive method for localizing hyperfunctioning, enlarged parathyroid glands or tissue in normal anatomic positions or ectopic locations. Uptake is enhanced and prolonged in parathyroid adenomas as well as in aberrant tissue found in the mediastinum or subclavicular areas. Sestamibi parathyroid scan detects up to 89% of single adenomas, but studies of this imaging modality have demonstrated a wide range of sensitivities (44%-95%).^5,17 A drawback of nuclear medicine studies is that they provide little anatomic detail.¹⁷ Nonetheless, the ability of the parathyroid scan to locate parathyroid glands has contributed to the success of the minimally invasive parathyroidectomy, and it is considered the most successful imaging modality available.^5,10 Identifying the precise location of the parathyroid adenoma is essential for a successful surgical outcome; this is best achieved by combining the sestamibi parathyroid scan with CT.¹²

Emerging imaging modalities are the multidetector CT (MDCT) and 4D-CT techniques. In an evaluation of the diagnostic accuracy of contrast-enhanced MDCT in the detection of parathyroid adenomas and aberrant parathyroid tissue, MDCT demonstrated the ability to differentiate between adenomas and hyperplasia and display important anatomic structures such as nerves and blood vessels.¹⁷ The specificity of MDCT for ruling out abnormal parathyroid tissue was 75%, and the sensitivity for detecting a single adenoma was 80%. Overall, MDCT demonstrated an 88% positive predictive value (PPV) in localizing hyperfunctioning parathyroid glands but showed poor sensitivity in detecting multigland disease.¹⁷ The PPV is a key value in determining the ability of an imaging study to precisely locate aberrant parathyroid tissue. MDCT provides detailed definition of anatomy, locating ectopic parathyroid glands in the deeper paraesophageal areas and mediastinum while defining relationships between the tissue and its surrounding vasculature, lymph nodes, and thyroid tissue.¹⁷ The 4D-CT technique employs three-dimensional technology and accounts for the movement of the patient’s body over time (the “fourth dimension”). It is an accurate method for identifying parathyroid adenomas but exposes the patient to higher radiation doses.¹⁸ The sensitivity of 4D-CT in localizing abnormal parathyroid tissue is comparable to that of MDCT.^16,18,19

Additional studies used during the management of the patient with PHPT are BMD testing and renal imaging. Secondary causes of bone loss are responsible for up to 30% of osteoporosis cases in postmenopausal women; one of these causes is PHPT.²⁰ Elevated PTH causes increased bone turnover and results in decreased bone mass with subsequent increased fracture risk.⁹ Bone density should be measured by dual-energy x-ray absorptiometry (DEXA), and the skeletal survey should include the distal one-third of the radius, hip, and lumbar spine. The distal radius is rich in cortical bone and BMD is often lowest at this site in patients with PHPT, making it the most sensitive DEXA marker for early detection of bone loss.^19,21 The hip contains an equal mix of cortical and trabecular bone and is the second most sensitive site for detecting bone loss in PHPT. The spine contains a high proportion of trabecular bone and is the least sensitive site.^19,21 Renal imaging studies, including x-ray, ultrasound, and, less frequently, CT of the abdomen and pelvis, are used to assess for nephrolithiasis and nephrocalcinosis.¹⁹

TREATMENT/MANAGEMENT

Conservative medical management

PHPT is a complex disease process, and careful evaluation is required when determining whether medical versus surgical management is appropriate. Clinical presentation ranges from no symptoms to multisystem disease. Conservative medical management, which includes regular monitoring, is an acceptable strategy in an asymptomatic patient with a low fracture risk and no nephrolithiasis.¹ Conservative care includes maintaining normal dietary calcium intake and adequate hydration, regular exercise, vitamin D supplementation, annual laboratory studies, BMD testing, and the avoidance of thiazide diuretics and lithium.¹ Guidelines, from the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism, for monitoring asymptomatic PHPT patients recommend

1. Annual measurement of serum calcium
2. BMD measurement by DEXA every 1 to 2 years
3. Annual assessment of eGFR and serum creatinine
4. Renal imaging or a 24-h urine stone profile if nephrolithiasis is suspected.¹⁹

Long-term medical management of PHPT is difficult because no agents are available to suppress hypercalcemia or completely block PTH release.¹²

Maintaining serum 25(OH)D at a level > 20 ng/mL significantly reduces PTH secretion, in comparison to levels < 20 ng/mL, and does not aggravate hypercalcemia.²² The Endocrine Society recommends a minimum serum 25(OH)D level of 20 ng/mL and notes that targeting a higher threshold value of 30 ng/mL is reasonable.¹⁹ The daily requirement for vitamin D3, 800 IU to 1,000 IU, is a good starting point for supplementation.⁴ Measurement of 1,25(OH)₂D levels lacks value and is not recommended for patients with PHPT. Calcium intake should follow established guidelines and is not limited in PHPT.¹⁹

Surgical management

Surgical management is indicated for symptomatic patients.²³ Indications include nephrolithiasis, nephrocalcinosis, osteitis fibrosa cystica, or osteoporosis. Surgery is considered appropriate for individuals who do not meet these criteria if there are no medical contraindications.¹⁴ The Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism revised the indications for surgery in 2014 to include asymptomatic patients, since surgery is the only definitive treatment for PHPT. Current guidelines for when to recommend surgery in the asymptomatic patient with PHPT are listed in Table 4.¹⁹

Preoperative localization and referral to an experienced surgeon is of utmost importance for a good outcome. An expert surgeon will usually perform a minimally invasive parathyroidectomy (MIP) and obtain intraoperative PTH levels; in some cases, a full neck exploration is necessary. PTH has a half-life of less than five minutes and is an accurate tool for determining whether the culprit gland has been successfully removed.⁵

Modern imaging studies, less invasive surgical techniques, and intraoperative measurements of PTH have decreased the need to conduct full neck exploration. MIP offers a smaller incision, less tissue dissection, and lower morbidity, and can be offered without the risks associated with general anesthesia.¹⁰ The goal of surgery is to restore normocalcemia and, in turn, prevent bone mineral loss and systemic effects of hypercalcemia over the long term.¹⁰ Surgical management for an ectopic parathyroid adenoma is controversial because these are often found in the mediastinum, requiring invasive surgery.¹²

Surgery is curative in up to 95% of cases and has a low rate of complications.^2,24 A joint decision regarding treatment options is made among the patient, primary care clinician, and surgeon. Complications include vocal cord paralysis resulting from injury to the recurrent laryngeal nerve, bleeding or hematoma, laryngospasm, symptomatic hypocalcemia, and persistent hyperparathyroidism; seizures are very rare but can occur from transient hypocalcemia and hypomagnesemia.⁵ PTH levels drop by more than 50% intraoperatively if the procedure is successful; otherwise, exploration for another adenoma is indicated.¹⁰ Postoperative calcium and vitamin D supplementation are warranted once lab values are stable.

When surgery is contraindicated/refused

If surgery is indicated but the patient is a poor candidate or refuses surgery, management of hypercalcemia and bone loss with pharmacologic agents is warranted. The calcimimetic cinacalcet is a reasonable medical alternative that has been shown to adequately control hypercalcemia and hypophosphatemia and has proven effective in various patient subgroups.²⁵ This agent is useful in the treatment of patients who are asymptomatic and refuse surgery, patients with refractory PHPT after parathyroidectomy, and patients with contraindications to surgery.^24,25 The medication reduces calcium and modestly reduces PTH levels by binding parathyroid calcium-sensing receptors but does not improve bone density.^2,12 Cinacalcet is approved by the FDA for use in patients with moderate to severe disease when surgery is contraindicated.²⁴

Treatment options for osteoporosis, vertebral fractures, and progressive bone loss in the patient with PHPT include bisphosphonates. Raloxifene and estrogen replacements may be used in postmenopausal women. Oral bisphosphonates (alendronate or risedronate) are firstline therapies and have been shown to inhibit progression to osteoporosis in PHPT.^9,26 They prevent osteoclastic activity, reducing bone resorption and turnover. Contraindications to oral bisphosphonates include esophageal disorders, gastrointestinal intolerance, or inability to follow the dosing requirements. Intravenous zoledronic acid provides an alternative route of administration.

Alendronate has the best evidence for improving bone density and preventing progression to osteoporosis in patients with PHPT, but the medication does not affect calcium or PTH levels.^1,19 There is limited data on the effects of combining bisphosphonates with calcimimetics. Raloxifene is a selective estrogen receptor modulator that decreases bone resorption; it is approved for treating osteoporosis and may be used when a patient is not a good candidate for a bisphosphonate.²⁰ Denosumab, currently under study for the treatment of PHPT, is a human monoclonal antibody that improves bone density but does not affect serum calcium.²⁰ Nonpharmacologic therapies include alcohol moderation, decreased caffeine intake, weight-bearing exercise, smoking cessation, adequate hydration, and dietary modifications.²⁰

OUTCOME FOR THE CASE PATIENT

Although PHPT is often discovered incidentally in routine blood work with hypercalcemia, the case patient had developed osteoporosis and a grade IV tibial stress fracture before the diagnosis was made. Following parathyroidectomy, her hypertension worsened, requiring an additional antihypertensive medication. She developed recurrent disease and was referred to a tertiary care center for revision parathyroidectomy due to persistent elevated calcium levels. A 24-hour urine calcium test ruled out concurrent FHH. A full neck exploration was conducted and a 340-mg hypercellular parathyroid gland was removed from the left superior pole. She will be monitored for recurrent disease and will remain on a vitamin D3 supplement and treatment for osteoporosis.

CONCLUSION

Primary care clinicians should have a low threshold for initiating the work-up of mild hypercalcemia in an effort to prevent sequelae. Patient education is essential throughout the process. Understanding the condition and treatment options is necessary for a patient’s active participation in clinical decision making. Conservative management of an asymptomatic patient includes avoiding thiazide diuretics and lithium, staying well hydrated with water, maintaining moderate dietary calcium (1,000-1,200 mg/d) and vitamin D (400-600 IU/d) intake, regular exercise, and appropriate lab and bone density monitoring. Surgical treatment is recommended for symptomatic patients exhibiting decreased bone density, fractures, renal impairment, or nephrolithiasis. Treating bone loss with bisphosphonates and hypercalcemia with calcimimetics is useful. Postmenopausal women may benefit from estrogen therapy or selective estrogen receptor modulators. These agents improve bone density and lower calcium, but are often contraindicated or have adverse effects. Surgery is the only cure.³

Apraxia of Eyelid Opening

Apraxia of eyelid opening sometimes is associated with Parkinson’s disease and parkinsonian disorders such as progressive supranuclear palsy. Patients with this condition may be unable to open their eyes without contracting the frontalis muscle. The literature contains no randomized controlled trials of botulinum toxin for this indication, but open-label studies, such as one from Inoue and Rogers, suggest a benefit. Reports indicate that the pretarsal is the most appropriate injection target. An initial dose of 10–20 units of onabotulinum or incobotulinum toxin can be administered to the orbicularis oculi.

Sialorrhea

Sialorrhea is common among patients with Parkinson’s disease and may result from impaired swallowing or autonomic dysregulation. Anticholinergic drugs such as glycopyrrolate often have limited efficacy for sialorrhea and may cause side effects. Several randomized controlled trials have examined botulinum toxin as a potential treatment. A review by Seppi et al concluded that botulinum toxin types A and B are efficacious for this indication, although it is an off-label use.

Two injection sites have been considered for this treatment: the submandibular gland, which is responsible for continuous saliva secretion, and the parotid gland, which is responsible for stimulated secretion. Most studies have used the parotid gland or the parotid and submandibular glands as targets. One small study directly compared the two injection sites and found a trend toward a greater benefit from injection into the submandibular gland. “One approach could be to inject the parotid gland, and if it is still not effective, you can inject the submandibular gland,” said Dr. Chen. The dose for the parotid gland ranges between 5 and 50 units of onabotulinum or incobotulinum toxin, and a dose of 5 units generally is used for the submandibular gland.

The injection site may be localized using ultrasound or anatomical landmarks. A study in which the target was the parotid gland found slightly better results with ultrasound guidance, but ultrasound may be more necessary for injections into the submandibular gland, said Dr. Chen. Whether ultrasound guidance improves outcomes of botulinum toxin for sialorrhea thus has not been established, he added.

Jaw Tremor and Upper-Limb Tremor

Levodopa is the first-line treatment for tremor in Parkinson’s disease, but some patients do not respond well to this therapy. Schneider and colleagues studied abobotulinum toxin for jaw tremor in Parkinson’s disease. They administered the treatment to three people through bilateral masseter injection. Patients had an excellent response without side effects. Another protocol is an injection of 40 units of onabotulinum or incobotulinum toxin into the masseter and 10 units into the temporalis, said Dr. Chen.

No randomized controlled trials of botulinum toxin for arm tremor related to Parkinson’s disease have been published, but Rahimi et al published two case series. In one series published in 2015, the investigators administered injections to 28 patients at baseline, 16 weeks, and 32 weeks. The study was open-label, and muscles were selected using kinematic analysis. They found reduced tremor with treatment, and patients had mild muscle weakness.

Dystonia

Patients with Parkinson’s disease or multiple system atrophy may develop cervical dystonia that manifests as anterocollis. Patients with progressive supranuclear palsy may develop retrocollis. Although botulinum toxin is not indicated for it, case reports suggest that the treatment may be effective for cervical dystonia. The sternomastoid, scalene, and the longus colli are appropriate injection targets. Neurologists may need imaging guidance to inject botulinum toxin into the longus colli. For one patient with cervical dystonia secondary to corticobasal syndrome, Dr. Chen administered 30 units (onabotulinum or incobotulinum toxin) to the right trapezius, 60 units to the levator scapulae, and 20 units to the sternomastoid.

Dystonic clenched fists also may occur in Parkinson’s disease and Parkinson-plus syndromes. In 2001, Cordivari et al studied botulinum toxin as a treatment for dystonic clenched fists in seven patients with Parkinson’s disease and seven patients with other disorders. The researchers used electromyography to distinguish between muscle contraction and contracture. The injection sites were the flexor digitorum superficialis, flexor digitorum profundus, flexor pollicis longus, and lumbricals. The treatment reduced pain, relaxed muscles, and helped to resolve palmar infections.

Leg dystonia can be a presenting symptom in young-onset Parkinson’s disease and sometimes is observed in peak-dose dyskinesia. However, the typical presentation is off-period foot inversion and toe flexion. The big toe may be flexed or extended. The largest study of botulinum toxin for leg dystonia included 30 patients with Parkinson’s disease and painful off dystonia and was published in 1995. Open-label treatment improved pain and spasm for all patients, and seven patients with on dystonia had improved posture on walking. In 2016, Gupta et al administered 250–400 units of onabotulinum toxin to six patients with Parkinson’s disease and leg dystonia treated with deep brain stimulation. The treatment improved dystonia, pain, walking, gait velocity, and cadence.

Pain

Neurologists also have used botulinum toxin to treat pain in Parkinson’s disease. Bruno and colleagues performed a retrospective chart review of patients with Parkinson’s disease who received botulinum toxin for various indications over a 20-year period. The main indication for treatment was pain, and 81% of patients who received botulinum toxin for pain reported benefit after the first injection. The benefit was sustained with further injections.

Overactive Bladder

Overactive bladder affects between 38% and 71% of people with Parkinson’s disease. Symptoms include urinary urgency, urinary frequency, nocturia, and incontinence. Behavioral modification is the first-line treatment, and antimuscarinic agents may provide benefit. Overactive bladder is an approved indication for onabotulinum toxin. The usual dose is 200 units, but it can range between 100 and 300 units. Treatment is injected into the detrusor muscles, and the benefit lasts for six months to nine months. Urine retention is a potential side effect of this treatment.

—Erik Greb

Suggested Reading

Bruno VA, Fox SH, Mancini D, Miyasaki JM. Botulinum toxin use in refractory pain and other symptoms in parkinsonism. Can J Neurol Sci. 2016;43(5):697-702.

Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 2001;16(5):907-913.

Giannantoni A, Conte A, Proietti S, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011;186(3):960-964.

Glass GA, Ku S, Ostrem JL, et al. Fluoroscopic, EMG-guided injection of botulinum toxin into the longus colli for the treatment of anterocollis. Parkinsonism Relat Disord. 2009;15(8):610-613.

Gupta AD, Visvanathan R. Botulinum toxin for foot dystonia in patients with Parkinson’s disease having deep brain stimulation: A case series and a pilot study. J Rehabil Med. 2016;48(6):559-562.

Inoue K, Rogers JD. Botulinum toxin injection into Riolan’s muscle: somatosensory ‘trick’. Eur Neurol. 2007;58(3):138-141.

Pacchetti C, Albani G, Martignoni E, et al. “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord. 1995;10(3):333-336.

Rahimi F, Samotus O, Lee J, Jog M. Effective management of upper limb parkinsonian tremor by incobotulinumtoxinA injections using sensor-based biomechanical patterns. Tremor Other Hyperkinet Mov (NY). 2015;5:348.

Schneider SA, Edwards MJ, Cordivari C, et al. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson’s disease. Mov Disord. 2006;21(10):1722-1724.

Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26 Suppl 3:S42-S80.

Apraxia of Eyelid Opening

Apraxia of eyelid opening sometimes is associated with Parkinson’s disease and parkinsonian disorders such as progressive supranuclear palsy. Patients with this condition may be unable to open their eyes without contracting the frontalis muscle. The literature contains no randomized controlled trials of botulinum toxin for this indication, but open-label studies, such as one from Inoue and Rogers, suggest a benefit. Reports indicate that the pretarsal is the most appropriate injection target. An initial dose of 10–20 units of onabotulinum or incobotulinum toxin can be administered to the orbicularis oculi.

Sialorrhea

Sialorrhea is common among patients with Parkinson’s disease and may result from impaired swallowing or autonomic dysregulation. Anticholinergic drugs such as glycopyrrolate often have limited efficacy for sialorrhea and may cause side effects. Several randomized controlled trials have examined botulinum toxin as a potential treatment. A review by Seppi et al concluded that botulinum toxin types A and B are efficacious for this indication, although it is an off-label use.

Two injection sites have been considered for this treatment: the submandibular gland, which is responsible for continuous saliva secretion, and the parotid gland, which is responsible for stimulated secretion. Most studies have used the parotid gland or the parotid and submandibular glands as targets. One small study directly compared the two injection sites and found a trend toward a greater benefit from injection into the submandibular gland. “One approach could be to inject the parotid gland, and if it is still not effective, you can inject the submandibular gland,” said Dr. Chen. The dose for the parotid gland ranges between 5 and 50 units of onabotulinum or incobotulinum toxin, and a dose of 5 units generally is used for the submandibular gland.

The injection site may be localized using ultrasound or anatomical landmarks. A study in which the target was the parotid gland found slightly better results with ultrasound guidance, but ultrasound may be more necessary for injections into the submandibular gland, said Dr. Chen. Whether ultrasound guidance improves outcomes of botulinum toxin for sialorrhea thus has not been established, he added.

Jaw Tremor and Upper-Limb Tremor

Levodopa is the first-line treatment for tremor in Parkinson’s disease, but some patients do not respond well to this therapy. Schneider and colleagues studied abobotulinum toxin for jaw tremor in Parkinson’s disease. They administered the treatment to three people through bilateral masseter injection. Patients had an excellent response without side effects. Another protocol is an injection of 40 units of onabotulinum or incobotulinum toxin into the masseter and 10 units into the temporalis, said Dr. Chen.

No randomized controlled trials of botulinum toxin for arm tremor related to Parkinson’s disease have been published, but Rahimi et al published two case series. In one series published in 2015, the investigators administered injections to 28 patients at baseline, 16 weeks, and 32 weeks. The study was open-label, and muscles were selected using kinematic analysis. They found reduced tremor with treatment, and patients had mild muscle weakness.

Dystonia

Patients with Parkinson’s disease or multiple system atrophy may develop cervical dystonia that manifests as anterocollis. Patients with progressive supranuclear palsy may develop retrocollis. Although botulinum toxin is not indicated for it, case reports suggest that the treatment may be effective for cervical dystonia. The sternomastoid, scalene, and the longus colli are appropriate injection targets. Neurologists may need imaging guidance to inject botulinum toxin into the longus colli. For one patient with cervical dystonia secondary to corticobasal syndrome, Dr. Chen administered 30 units (onabotulinum or incobotulinum toxin) to the right trapezius, 60 units to the levator scapulae, and 20 units to the sternomastoid.

Dystonic clenched fists also may occur in Parkinson’s disease and Parkinson-plus syndromes. In 2001, Cordivari et al studied botulinum toxin as a treatment for dystonic clenched fists in seven patients with Parkinson’s disease and seven patients with other disorders. The researchers used electromyography to distinguish between muscle contraction and contracture. The injection sites were the flexor digitorum superficialis, flexor digitorum profundus, flexor pollicis longus, and lumbricals. The treatment reduced pain, relaxed muscles, and helped to resolve palmar infections.

Leg dystonia can be a presenting symptom in young-onset Parkinson’s disease and sometimes is observed in peak-dose dyskinesia. However, the typical presentation is off-period foot inversion and toe flexion. The big toe may be flexed or extended. The largest study of botulinum toxin for leg dystonia included 30 patients with Parkinson’s disease and painful off dystonia and was published in 1995. Open-label treatment improved pain and spasm for all patients, and seven patients with on dystonia had improved posture on walking. In 2016, Gupta et al administered 250–400 units of onabotulinum toxin to six patients with Parkinson’s disease and leg dystonia treated with deep brain stimulation. The treatment improved dystonia, pain, walking, gait velocity, and cadence.

Pain

Neurologists also have used botulinum toxin to treat pain in Parkinson’s disease. Bruno and colleagues performed a retrospective chart review of patients with Parkinson’s disease who received botulinum toxin for various indications over a 20-year period. The main indication for treatment was pain, and 81% of patients who received botulinum toxin for pain reported benefit after the first injection. The benefit was sustained with further injections.

Overactive Bladder

Overactive bladder affects between 38% and 71% of people with Parkinson’s disease. Symptoms include urinary urgency, urinary frequency, nocturia, and incontinence. Behavioral modification is the first-line treatment, and antimuscarinic agents may provide benefit. Overactive bladder is an approved indication for onabotulinum toxin. The usual dose is 200 units, but it can range between 100 and 300 units. Treatment is injected into the detrusor muscles, and the benefit lasts for six months to nine months. Urine retention is a potential side effect of this treatment.

—Erik Greb

Suggested Reading

Bruno VA, Fox SH, Mancini D, Miyasaki JM. Botulinum toxin use in refractory pain and other symptoms in parkinsonism. Can J Neurol Sci. 2016;43(5):697-702.

Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 2001;16(5):907-913.

Giannantoni A, Conte A, Proietti S, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011;186(3):960-964.

Glass GA, Ku S, Ostrem JL, et al. Fluoroscopic, EMG-guided injection of botulinum toxin into the longus colli for the treatment of anterocollis. Parkinsonism Relat Disord. 2009;15(8):610-613.

Gupta AD, Visvanathan R. Botulinum toxin for foot dystonia in patients with Parkinson’s disease having deep brain stimulation: A case series and a pilot study. J Rehabil Med. 2016;48(6):559-562.

Inoue K, Rogers JD. Botulinum toxin injection into Riolan’s muscle: somatosensory ‘trick’. Eur Neurol. 2007;58(3):138-141.

Pacchetti C, Albani G, Martignoni E, et al. “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord. 1995;10(3):333-336.

Rahimi F, Samotus O, Lee J, Jog M. Effective management of upper limb parkinsonian tremor by incobotulinumtoxinA injections using sensor-based biomechanical patterns. Tremor Other Hyperkinet Mov (NY). 2015;5:348.

Schneider SA, Edwards MJ, Cordivari C, et al. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson’s disease. Mov Disord. 2006;21(10):1722-1724.

Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26 Suppl 3:S42-S80.

Apraxia of Eyelid Opening

Apraxia of eyelid opening sometimes is associated with Parkinson’s disease and parkinsonian disorders such as progressive supranuclear palsy. Patients with this condition may be unable to open their eyes without contracting the frontalis muscle. The literature contains no randomized controlled trials of botulinum toxin for this indication, but open-label studies, such as one from Inoue and Rogers, suggest a benefit. Reports indicate that the pretarsal is the most appropriate injection target. An initial dose of 10–20 units of onabotulinum or incobotulinum toxin can be administered to the orbicularis oculi.

Sialorrhea

Sialorrhea is common among patients with Parkinson’s disease and may result from impaired swallowing or autonomic dysregulation. Anticholinergic drugs such as glycopyrrolate often have limited efficacy for sialorrhea and may cause side effects. Several randomized controlled trials have examined botulinum toxin as a potential treatment. A review by Seppi et al concluded that botulinum toxin types A and B are efficacious for this indication, although it is an off-label use.

Two injection sites have been considered for this treatment: the submandibular gland, which is responsible for continuous saliva secretion, and the parotid gland, which is responsible for stimulated secretion. Most studies have used the parotid gland or the parotid and submandibular glands as targets. One small study directly compared the two injection sites and found a trend toward a greater benefit from injection into the submandibular gland. “One approach could be to inject the parotid gland, and if it is still not effective, you can inject the submandibular gland,” said Dr. Chen. The dose for the parotid gland ranges between 5 and 50 units of onabotulinum or incobotulinum toxin, and a dose of 5 units generally is used for the submandibular gland.

The injection site may be localized using ultrasound or anatomical landmarks. A study in which the target was the parotid gland found slightly better results with ultrasound guidance, but ultrasound may be more necessary for injections into the submandibular gland, said Dr. Chen. Whether ultrasound guidance improves outcomes of botulinum toxin for sialorrhea thus has not been established, he added.

Jaw Tremor and Upper-Limb Tremor

Levodopa is the first-line treatment for tremor in Parkinson’s disease, but some patients do not respond well to this therapy. Schneider and colleagues studied abobotulinum toxin for jaw tremor in Parkinson’s disease. They administered the treatment to three people through bilateral masseter injection. Patients had an excellent response without side effects. Another protocol is an injection of 40 units of onabotulinum or incobotulinum toxin into the masseter and 10 units into the temporalis, said Dr. Chen.

No randomized controlled trials of botulinum toxin for arm tremor related to Parkinson’s disease have been published, but Rahimi et al published two case series. In one series published in 2015, the investigators administered injections to 28 patients at baseline, 16 weeks, and 32 weeks. The study was open-label, and muscles were selected using kinematic analysis. They found reduced tremor with treatment, and patients had mild muscle weakness.

Dystonia

Patients with Parkinson’s disease or multiple system atrophy may develop cervical dystonia that manifests as anterocollis. Patients with progressive supranuclear palsy may develop retrocollis. Although botulinum toxin is not indicated for it, case reports suggest that the treatment may be effective for cervical dystonia. The sternomastoid, scalene, and the longus colli are appropriate injection targets. Neurologists may need imaging guidance to inject botulinum toxin into the longus colli. For one patient with cervical dystonia secondary to corticobasal syndrome, Dr. Chen administered 30 units (onabotulinum or incobotulinum toxin) to the right trapezius, 60 units to the levator scapulae, and 20 units to the sternomastoid.

Dystonic clenched fists also may occur in Parkinson’s disease and Parkinson-plus syndromes. In 2001, Cordivari et al studied botulinum toxin as a treatment for dystonic clenched fists in seven patients with Parkinson’s disease and seven patients with other disorders. The researchers used electromyography to distinguish between muscle contraction and contracture. The injection sites were the flexor digitorum superficialis, flexor digitorum profundus, flexor pollicis longus, and lumbricals. The treatment reduced pain, relaxed muscles, and helped to resolve palmar infections.

Leg dystonia can be a presenting symptom in young-onset Parkinson’s disease and sometimes is observed in peak-dose dyskinesia. However, the typical presentation is off-period foot inversion and toe flexion. The big toe may be flexed or extended. The largest study of botulinum toxin for leg dystonia included 30 patients with Parkinson’s disease and painful off dystonia and was published in 1995. Open-label treatment improved pain and spasm for all patients, and seven patients with on dystonia had improved posture on walking. In 2016, Gupta et al administered 250–400 units of onabotulinum toxin to six patients with Parkinson’s disease and leg dystonia treated with deep brain stimulation. The treatment improved dystonia, pain, walking, gait velocity, and cadence.

Pain

Neurologists also have used botulinum toxin to treat pain in Parkinson’s disease. Bruno and colleagues performed a retrospective chart review of patients with Parkinson’s disease who received botulinum toxin for various indications over a 20-year period. The main indication for treatment was pain, and 81% of patients who received botulinum toxin for pain reported benefit after the first injection. The benefit was sustained with further injections.

Overactive Bladder

Overactive bladder affects between 38% and 71% of people with Parkinson’s disease. Symptoms include urinary urgency, urinary frequency, nocturia, and incontinence. Behavioral modification is the first-line treatment, and antimuscarinic agents may provide benefit. Overactive bladder is an approved indication for onabotulinum toxin. The usual dose is 200 units, but it can range between 100 and 300 units. Treatment is injected into the detrusor muscles, and the benefit lasts for six months to nine months. Urine retention is a potential side effect of this treatment.

—Erik Greb

Suggested Reading

Bruno VA, Fox SH, Mancini D, Miyasaki JM. Botulinum toxin use in refractory pain and other symptoms in parkinsonism. Can J Neurol Sci. 2016;43(5):697-702.

Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 2001;16(5):907-913.

Giannantoni A, Conte A, Proietti S, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011;186(3):960-964.

Glass GA, Ku S, Ostrem JL, et al. Fluoroscopic, EMG-guided injection of botulinum toxin into the longus colli for the treatment of anterocollis. Parkinsonism Relat Disord. 2009;15(8):610-613.

Gupta AD, Visvanathan R. Botulinum toxin for foot dystonia in patients with Parkinson’s disease having deep brain stimulation: A case series and a pilot study. J Rehabil Med. 2016;48(6):559-562.

Inoue K, Rogers JD. Botulinum toxin injection into Riolan’s muscle: somatosensory ‘trick’. Eur Neurol. 2007;58(3):138-141.

Pacchetti C, Albani G, Martignoni E, et al. “Off” painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord. 1995;10(3):333-336.

Rahimi F, Samotus O, Lee J, Jog M. Effective management of upper limb parkinsonian tremor by incobotulinumtoxinA injections using sensor-based biomechanical patterns. Tremor Other Hyperkinet Mov (NY). 2015;5:348.

Schneider SA, Edwards MJ, Cordivari C, et al. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson’s disease. Mov Disord. 2006;21(10):1722-1724.

Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26 Suppl 3:S42-S80.

AT ENDO 2017

ORLANDO – Endocrinologists made up about one in four of the practitioners performing fine needle aspiration (FNA) biopsies between 2012 and 2014, according to a review of data from the Centers for Medicare & Medicaid Services.

Similarly, endocrinologists performed 25% of image-guided thyroid biopsies.

Endocrine surgeons represent only a small percentage of all practitioners performing head and neck ultrasound exams and image-guided FNA, lead author Mamoona Khokhar, MD, said during a poster presentation at the annual meeting of the Endocrine Society. This is true even though the more portable nature of ultrasound has made it easier for motivated surgeons to incorporate its use into their practice, she said.

Examining 3 years of data from a provider utilization and payment database, Dr. Khokhar and her colleagues identified the types of practitioners who performed head and neck ultrasound, as well as image-guided FNA.

In their analysis, the researchers broadly divided practitioners into surgeons and nonsurgeons. Overall, of the 14,750 median annual practitioners performing head and neck ultrasound between 2012 and 2014, 97.2% were nonsurgeon practitioners, reported Dr. Khokhar, an endocrine surgery fellow at Columbia University Medical Center in New York.

Of all practitioners performing head and neck ultrasound, most (81%) were radiologists. Endocrinologists made up 8% of the overall pool performing ultrasounds.

Breaking the surgeon group down further showed that endocrine surgeons represented 14.7% of surgeons performing head and neck ultrasound, meaning that they made up just 0.4% of the practitioner pool for this procedure. Just over half (52%) of the surgeons performing ultrasounds were otolaryngologists.

The number of practitioners performing image-guided FNA was smaller, at a median 3,695 per year during the study period. Surgeons made up 10.7% of this number. Of the surgeons who performed image-guided FNA, 10.5% were endocrine surgeons. Endocrine surgeons made up 1.1% of all practitioners who billed for FNA.

Again, radiologists made up the majority (58%) of the practitioners performing FNA, and one in four (25%) of practitioners performing FNAs were endocrinologists. Just 5% of the practitioners performing FNAs were otolaryngologists.

More endocrine surgeons performed ultrasound than advanced practice providers (nurse practitioners or physician assistants, 0.2%), pathologists (0.1%), and surgical oncologists (0.04%; P for all, less than .0001). However, advanced practice providers and pathologists both performed significantly more FNAs than did endocrine surgeons (2.1% and 1.8%, P less than .0001).

Although the raw proportion of endocrine surgeons billing for these procedures increased during the study period, the increases were not statistically significant. Dr. Khokhar and her colleagues found that the proportion of American Association of Endocrine Surgeons members who performed head and neck ultrasound grew from 59% in 2012 to 72% in 2014 (^P = 0.37), while the proportion performing FNA also increased, from 36% in 2012 to 46% in 2014 (P = .40).

Surgeons, however, may face a number of obstacles in setting up office-based ultrasound, which can lead to underutilization by surgeons, Dr. Khokhar noted, adding that “the results of this study suggest that endocrine surgeons may not be fully utilizing this critical tool in their clinical practice.”

The authors reported no outside sources of funding, and had no relevant conflicts of interest.
 

[email protected]

On Twitter @karioakes

AT ENDO 2017

ORLANDO – Endocrinologists made up about one in four of the practitioners performing fine needle aspiration (FNA) biopsies between 2012 and 2014, according to a review of data from the Centers for Medicare & Medicaid Services.

Similarly, endocrinologists performed 25% of image-guided thyroid biopsies.

Endocrine surgeons represent only a small percentage of all practitioners performing head and neck ultrasound exams and image-guided FNA, lead author Mamoona Khokhar, MD, said during a poster presentation at the annual meeting of the Endocrine Society. This is true even though the more portable nature of ultrasound has made it easier for motivated surgeons to incorporate its use into their practice, she said.

Examining 3 years of data from a provider utilization and payment database, Dr. Khokhar and her colleagues identified the types of practitioners who performed head and neck ultrasound, as well as image-guided FNA.

In their analysis, the researchers broadly divided practitioners into surgeons and nonsurgeons. Overall, of the 14,750 median annual practitioners performing head and neck ultrasound between 2012 and 2014, 97.2% were nonsurgeon practitioners, reported Dr. Khokhar, an endocrine surgery fellow at Columbia University Medical Center in New York.

Of all practitioners performing head and neck ultrasound, most (81%) were radiologists. Endocrinologists made up 8% of the overall pool performing ultrasounds.

Breaking the surgeon group down further showed that endocrine surgeons represented 14.7% of surgeons performing head and neck ultrasound, meaning that they made up just 0.4% of the practitioner pool for this procedure. Just over half (52%) of the surgeons performing ultrasounds were otolaryngologists.

The number of practitioners performing image-guided FNA was smaller, at a median 3,695 per year during the study period. Surgeons made up 10.7% of this number. Of the surgeons who performed image-guided FNA, 10.5% were endocrine surgeons. Endocrine surgeons made up 1.1% of all practitioners who billed for FNA.

Again, radiologists made up the majority (58%) of the practitioners performing FNA, and one in four (25%) of practitioners performing FNAs were endocrinologists. Just 5% of the practitioners performing FNAs were otolaryngologists.

More endocrine surgeons performed ultrasound than advanced practice providers (nurse practitioners or physician assistants, 0.2%), pathologists (0.1%), and surgical oncologists (0.04%; P for all, less than .0001). However, advanced practice providers and pathologists both performed significantly more FNAs than did endocrine surgeons (2.1% and 1.8%, P less than .0001).

Although the raw proportion of endocrine surgeons billing for these procedures increased during the study period, the increases were not statistically significant. Dr. Khokhar and her colleagues found that the proportion of American Association of Endocrine Surgeons members who performed head and neck ultrasound grew from 59% in 2012 to 72% in 2014 (^P = 0.37), while the proportion performing FNA also increased, from 36% in 2012 to 46% in 2014 (P = .40).

Surgeons, however, may face a number of obstacles in setting up office-based ultrasound, which can lead to underutilization by surgeons, Dr. Khokhar noted, adding that “the results of this study suggest that endocrine surgeons may not be fully utilizing this critical tool in their clinical practice.”

The authors reported no outside sources of funding, and had no relevant conflicts of interest.
 

[email protected]

On Twitter @karioakes

AT ENDO 2017

ORLANDO – Endocrinologists made up about one in four of the practitioners performing fine needle aspiration (FNA) biopsies between 2012 and 2014, according to a review of data from the Centers for Medicare & Medicaid Services.

Similarly, endocrinologists performed 25% of image-guided thyroid biopsies.

Endocrine surgeons represent only a small percentage of all practitioners performing head and neck ultrasound exams and image-guided FNA, lead author Mamoona Khokhar, MD, said during a poster presentation at the annual meeting of the Endocrine Society. This is true even though the more portable nature of ultrasound has made it easier for motivated surgeons to incorporate its use into their practice, she said.

Examining 3 years of data from a provider utilization and payment database, Dr. Khokhar and her colleagues identified the types of practitioners who performed head and neck ultrasound, as well as image-guided FNA.

In their analysis, the researchers broadly divided practitioners into surgeons and nonsurgeons. Overall, of the 14,750 median annual practitioners performing head and neck ultrasound between 2012 and 2014, 97.2% were nonsurgeon practitioners, reported Dr. Khokhar, an endocrine surgery fellow at Columbia University Medical Center in New York.

Of all practitioners performing head and neck ultrasound, most (81%) were radiologists. Endocrinologists made up 8% of the overall pool performing ultrasounds.

Breaking the surgeon group down further showed that endocrine surgeons represented 14.7% of surgeons performing head and neck ultrasound, meaning that they made up just 0.4% of the practitioner pool for this procedure. Just over half (52%) of the surgeons performing ultrasounds were otolaryngologists.

The number of practitioners performing image-guided FNA was smaller, at a median 3,695 per year during the study period. Surgeons made up 10.7% of this number. Of the surgeons who performed image-guided FNA, 10.5% were endocrine surgeons. Endocrine surgeons made up 1.1% of all practitioners who billed for FNA.

Again, radiologists made up the majority (58%) of the practitioners performing FNA, and one in four (25%) of practitioners performing FNAs were endocrinologists. Just 5% of the practitioners performing FNAs were otolaryngologists.

More endocrine surgeons performed ultrasound than advanced practice providers (nurse practitioners or physician assistants, 0.2%), pathologists (0.1%), and surgical oncologists (0.04%; P for all, less than .0001). However, advanced practice providers and pathologists both performed significantly more FNAs than did endocrine surgeons (2.1% and 1.8%, P less than .0001).

Although the raw proportion of endocrine surgeons billing for these procedures increased during the study period, the increases were not statistically significant. Dr. Khokhar and her colleagues found that the proportion of American Association of Endocrine Surgeons members who performed head and neck ultrasound grew from 59% in 2012 to 72% in 2014 (^P = 0.37), while the proportion performing FNA also increased, from 36% in 2012 to 46% in 2014 (P = .40).

Surgeons, however, may face a number of obstacles in setting up office-based ultrasound, which can lead to underutilization by surgeons, Dr. Khokhar noted, adding that “the results of this study suggest that endocrine surgeons may not be fully utilizing this critical tool in their clinical practice.”

The authors reported no outside sources of funding, and had no relevant conflicts of interest.
 

[email protected]

On Twitter @karioakes

The World Health Organization is urging governments to focus antibiotic research efforts on a list of urgent bacterial threats, topped by several increasingly powerful superbugs that cause hospital-based infections and other potentially deadly conditions.

The WHO listed the top 20 bacteria that it believes are most harmful to human health, other than mycobacteria such as Mycobacterium tuberculosis, which causes tuberculosis. The germ was not included in the list because it’s generally accepted to be the most urgent priority for new antibiotic research and development, Marie-Paule Kieny, PhD, a WHO assistant director, said at a press conference.

The priority list is needed because the antibiotic pipeline is “practically dry,” thanks to scientific research challenges and a lack of financial incentives, according to Dr. Kieny. “Antibiotics are generally used for the short term, unlike therapies for chronic diseases, which bring in much higher returns on investment,” she said. The list “is intended to signal to the scientific community and the pharmaceutical industry the areas they should focus on to address urgent public health threats.”

MacXever/Thinkstock

The World Health Organization is urging governments to focus antibiotic research efforts on a list of urgent bacterial threats, topped by several increasingly powerful superbugs that cause hospital-based infections and other potentially deadly conditions.

The WHO listed the top 20 bacteria that it believes are most harmful to human health, other than mycobacteria such as Mycobacterium tuberculosis, which causes tuberculosis. The germ was not included in the list because it’s generally accepted to be the most urgent priority for new antibiotic research and development, Marie-Paule Kieny, PhD, a WHO assistant director, said at a press conference.

The priority list is needed because the antibiotic pipeline is “practically dry,” thanks to scientific research challenges and a lack of financial incentives, according to Dr. Kieny. “Antibiotics are generally used for the short term, unlike therapies for chronic diseases, which bring in much higher returns on investment,” she said. The list “is intended to signal to the scientific community and the pharmaceutical industry the areas they should focus on to address urgent public health threats.”

MacXever/Thinkstock

The World Health Organization is urging governments to focus antibiotic research efforts on a list of urgent bacterial threats, topped by several increasingly powerful superbugs that cause hospital-based infections and other potentially deadly conditions.

The WHO listed the top 20 bacteria that it believes are most harmful to human health, other than mycobacteria such as Mycobacterium tuberculosis, which causes tuberculosis. The germ was not included in the list because it’s generally accepted to be the most urgent priority for new antibiotic research and development, Marie-Paule Kieny, PhD, a WHO assistant director, said at a press conference.

The priority list is needed because the antibiotic pipeline is “practically dry,” thanks to scientific research challenges and a lack of financial incentives, according to Dr. Kieny. “Antibiotics are generally used for the short term, unlike therapies for chronic diseases, which bring in much higher returns on investment,” she said. The list “is intended to signal to the scientific community and the pharmaceutical industry the areas they should focus on to address urgent public health threats.”

MacXever/Thinkstock

Medical services overuse is the provision of healthcare services for which there is no medical basis or for which harms equal or exceed benefits.¹ This overuse drives poor-quality care and unnecessary cost.^2,3 The high prevalence of overuse is recognized by patients,⁴ clinicians,⁵ and policymakers.⁶ Initiatives to reduce overuse have targeted physicians,⁷ the public,⁸ and medical educators^9,10 but have had limited impact.^11,12 Few studies have addressed methods for reducing overuse, and de-implementation of nonbeneficial practices has proved challenging.^1,13,14 Models for reducing overuse are only theoretical¹⁵ or are focused on administrative decisions.^16,17 We think a practical framework is needed. We used an iterative process, informed by expert opinion and discussion, to design such a framework.

The authors, who have expertise in overuse, value, medical education, evidence-based medicine, and implementation science, reviewed related conceptual frameworks¹⁸ and evidence regarding drivers of overuse. We organized these drivers into domains to create a draft framework, which we presented at Preventing Overdiagnosis 2015, a meeting of clinicians, patients, and policymakers interested in overuse. We incorporated feedback from meeting attendees to modify framework domains, and we performed structured searches (using key words in Pubmed) to explore, and estimate the strength of, evidence supporting items within each domain. We rated supporting evidence as strong (studies found a clear correlation between a factor and overuse), moderate (evidence suggests such a correlation or demonstrates a correlation between a particular factor and utilization but not overuse per se), weak (only indirect evidence exists), or absent (no studies identified evaluating a particular factor). All authors reached consensus on ratings.

Framework Principles and Evidence

Patient-centered definition of overuse. During framework development, defining clinical appropriateness emerged as the primary challenge to identifying and reducing overuse. Although some care generally is appropriate based on strong evidence of benefit, and some is inappropriate given a clear lack of benefit or harm, much care is of unclear or variable benefit. Practice guidelines can help identify overuse, but their utility may be limited by lack of evidence in specific clinical situations,¹⁹ and their recommendations may apply poorly to an individual patient. This presents challenges to using guidelines to identify and reduce overuse.

Despite limitations, the scope of overuse has been estimated by applying broad, often guideline-based, criteria for care appropriateness to administrative data.²⁰ Unfortunately, these estimates provide little direction to clinicians and patients partnering to make usage decisions. During framework development, we identified the importance of a patient-level, patient-specific definition of overuse. This approach reinforces the importance of meeting patient needs while standardizing treatments to reduce overuse. A patient-centered approach may also assist professional societies and advocacy groups in developing actionable campaigns and may uncover evidence gaps.

Centrality of patient-clinician interaction. During framework development, the patient–clinician interaction emerged as the nexus through which drivers of overuse exert influence. The centrality of this interaction has been demonstrated in studies of the relationship between care continuity and overuse²¹ or utilization,^22,23 by evidence that communication and patient–clinician relationships affect utilization,²⁴ and by the observation that clinician training in shared decision-making reduces overuse.²⁵ A patient-centered framework assumes that, at least in the weighing of clinically reasonable options, a patient-centered approach optimizes outcomes for that patient.

Incorporating drivers of overuse. We incorporated drivers of overuse into domains and related them to the patient–clinician interaction.²⁶ Domains included the culture of healthcare consumption, patient factors and experiences, the practice environment, the culture of professional medicine, and clinician attitudes and beliefs.

We characterized the evidence illustrating how drivers within each domain influence healthcare use. The evidence for each domain is listed in Table 1.

The final framework is shown in the Figure. Within the healthcare system, patients are influenced by the culture of healthcare consumption, which varies within and among countries.²⁷ Clinicians are influenced by the culture of medical care, which varies by practice setting,²⁸ and by their training environment.²⁹ Both clinicians and patients are influenced by the practice environment and by personal experiences. Ultimately, clinical decisions occur within the specific patient–clinician interaction.²⁴ Table 1 lists each domain’s components, likely impact on overuse, and estimated strength of supporting evidence. Interventions can be conceptualized within appropriate domains or through the interaction between patient and clinician.

We developed a novel and practical conceptual framework for characterizing drivers of overuse and potential intervention points. To our knowledge, this is the first framework incorporating a patient-specific approach to overuse and emphasizing the patient–clinician interaction. Key strengths of framework development are inclusion of a range of perspectives and characterization of the evidence within each domain. Limitations include lack of a formal systematic review and broad, qualitative assessments of evidence strength. However, we believe this framework provides an important conceptual foundation for the study of overuse and interventions to reduce overuse.

Framework Applications

This framework, which highlights the many drivers of overuse, can facilitate understanding of overuse and help conceptualize change, prioritize research goals, and inform specific interventions. For policymakers, the framework can inform efforts to reduce overuse by emphasizing the need for complex interventions and by clarifying the likely impact of interventions targeting specific domains. Similarly, for clinicians and quality improvement professionals, the framework can ground root cause analyses of overuse-related problems and inform allocation of limited resources. Finally, the relatively weak evidence on the role of most acknowledged drivers of overuse suggests an important research agenda. Specifically, several pressing needs have been identified: defining relevant physician and patient cultural factors, investigating interventions to impact culture, defining practice environment features that optimize care appropriateness, and describing specific patient–clinician interaction practices that minimize overuse while providing needed care.

Targeting Interventions

Domains within the framework are influenced by different types of interventions, and different stakeholders may target different domains. For example:
 

• The culture of healthcare consumption may be influenced through public education (eg, Choosing Wisely^® patient resources)^30-32 and public health campaigns.
• The practice environment may be influenced by initiatives to align clinician incentives,³³ team care,³⁴ electronic health record interventions,³⁵ and improved access.³⁶
• Clinician attitudes and beliefs may be influenced by audit and feedback,^37-40 reflection,⁴¹ role modeling,⁴² and education.^43-45
• Patient attitudes and beliefs may be influenced by education, access to price and quality information, and increased engagement in care.^46,47
• For clinicians, the patient–clinician interaction can be improved through training in communication and shared decision-making,25 through access to information (eg, costs) that can be easily shared with patients,^48,49 and through novel visit structures (eg, scribes).⁵⁰
• On the patient side, this interaction can be optimized with improved access (eg, through telemedicine)^51,52 or with patient empowerment during hospitalization.
• The culture of medicine is difficult to influence. Change likely will occur through:

○ Regulatory interventions (eg, Transforming Clinical Practice Initiative of Center for Medicare & Medicaid Innovation).

○ Educational initiatives (eg, high-value care curricula of Alliance for Academic Internal Medicine/American College of Physicians⁵³).

○ Medical journal features (eg, “Less Is More” in JAMA Internal Medicine⁵⁴ and “Things We Do for No Reason” in Journal of Hospital Medicine).

○ Professional organizations (eg, Choosing Wisely^®).

As organizations implement quality improvement initiatives to reduce overuse of services, the framework can be used to target interventions to relevant domains. For example, a hospital leader who wants to reduce opioid prescribing may use the framework to identify the factors that encourage prescribing in each domain—poor understanding of pain treatment (a clinician factor), desire for early discharge encouraging overly aggressive pain management (an environmental factor), patient demand for opioids combined with poor understanding of harms (patient factors), and poor communication regarding pain (a patient–clinician interaction factor). Although not all relevant factors can be addressed, their classification by domain facilitates intervention, in this case perhaps leading to a focus on clinician and patient education on opioids and development of a practical communication tool that targets 3 domains. Table 2 lists ways in which the framework informs approaches to this and other overused services in the hospital setting. Note that some drivers can be acknowledged without identifying targeted interventions.

Moving Forward

Through a multi-stakeholder iterative process, we developed a practical framework for understanding medical overuse and interventions to reduce it. Centered on the patient–clinician interaction, this framework explains overuse as the product of medical and patient culture, the practice environment and incentives, and other clinician and patient factors. Ultimately, care is implemented during the patient–clinician interaction, though few interventions to reduce overuse have focused on that domain.

Conceptualizing overuse through the patient–clinician interaction maintains focus on patients while promoting population health that is both better and lower in cost. This framework can guide interventions to reduce overuse in important parts of the healthcare system while ensuring the final goal of high-quality individualized patient care.

Acknowledgments

The authors thank Valerie Pocus for helping with the artistic design of Framework. An early version of Framework was presented at the 2015 Preventing Overdiagnosis meeting in Bethesda, Maryland.

Disclosures

Dr. Morgan received research support from the VA Health Services Research (CRE 12-307), Agency for Healthcare Research and Quality (AHRQ) (K08- HS18111). Dr. Leppin’s work was supported by CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health (NIH). Dr. Korenstein’s work on this paper was supported by a Cancer Center Support Grant from the National Cancer Institute to Memorial Sloan Kettering Cancer Center (award number P30 CA008748). Dr. Morgan provided a self-developed lecture in a 3M-sponsored series on hospital epidemiology and has received honoraria for serving as a book and journal editor for Springer Publishing. Dr. Smith is employed by the American College of Physicians and owns stock in Merck, where her husband is employed. The other authors report no potential conflicts of interest.

Medical services overuse is the provision of healthcare services for which there is no medical basis or for which harms equal or exceed benefits.¹ This overuse drives poor-quality care and unnecessary cost.^2,3 The high prevalence of overuse is recognized by patients,⁴ clinicians,⁵ and policymakers.⁶ Initiatives to reduce overuse have targeted physicians,⁷ the public,⁸ and medical educators^9,10 but have had limited impact.^11,12 Few studies have addressed methods for reducing overuse, and de-implementation of nonbeneficial practices has proved challenging.^1,13,14 Models for reducing overuse are only theoretical¹⁵ or are focused on administrative decisions.^16,17 We think a practical framework is needed. We used an iterative process, informed by expert opinion and discussion, to design such a framework.

The authors, who have expertise in overuse, value, medical education, evidence-based medicine, and implementation science, reviewed related conceptual frameworks¹⁸ and evidence regarding drivers of overuse. We organized these drivers into domains to create a draft framework, which we presented at Preventing Overdiagnosis 2015, a meeting of clinicians, patients, and policymakers interested in overuse. We incorporated feedback from meeting attendees to modify framework domains, and we performed structured searches (using key words in Pubmed) to explore, and estimate the strength of, evidence supporting items within each domain. We rated supporting evidence as strong (studies found a clear correlation between a factor and overuse), moderate (evidence suggests such a correlation or demonstrates a correlation between a particular factor and utilization but not overuse per se), weak (only indirect evidence exists), or absent (no studies identified evaluating a particular factor). All authors reached consensus on ratings.

Framework Principles and Evidence

Patient-centered definition of overuse. During framework development, defining clinical appropriateness emerged as the primary challenge to identifying and reducing overuse. Although some care generally is appropriate based on strong evidence of benefit, and some is inappropriate given a clear lack of benefit or harm, much care is of unclear or variable benefit. Practice guidelines can help identify overuse, but their utility may be limited by lack of evidence in specific clinical situations,¹⁹ and their recommendations may apply poorly to an individual patient. This presents challenges to using guidelines to identify and reduce overuse.

Despite limitations, the scope of overuse has been estimated by applying broad, often guideline-based, criteria for care appropriateness to administrative data.²⁰ Unfortunately, these estimates provide little direction to clinicians and patients partnering to make usage decisions. During framework development, we identified the importance of a patient-level, patient-specific definition of overuse. This approach reinforces the importance of meeting patient needs while standardizing treatments to reduce overuse. A patient-centered approach may also assist professional societies and advocacy groups in developing actionable campaigns and may uncover evidence gaps.

Centrality of patient-clinician interaction. During framework development, the patient–clinician interaction emerged as the nexus through which drivers of overuse exert influence. The centrality of this interaction has been demonstrated in studies of the relationship between care continuity and overuse²¹ or utilization,^22,23 by evidence that communication and patient–clinician relationships affect utilization,²⁴ and by the observation that clinician training in shared decision-making reduces overuse.²⁵ A patient-centered framework assumes that, at least in the weighing of clinically reasonable options, a patient-centered approach optimizes outcomes for that patient.

Incorporating drivers of overuse. We incorporated drivers of overuse into domains and related them to the patient–clinician interaction.²⁶ Domains included the culture of healthcare consumption, patient factors and experiences, the practice environment, the culture of professional medicine, and clinician attitudes and beliefs.

We characterized the evidence illustrating how drivers within each domain influence healthcare use. The evidence for each domain is listed in Table 1.

The final framework is shown in the Figure. Within the healthcare system, patients are influenced by the culture of healthcare consumption, which varies within and among countries.²⁷ Clinicians are influenced by the culture of medical care, which varies by practice setting,²⁸ and by their training environment.²⁹ Both clinicians and patients are influenced by the practice environment and by personal experiences. Ultimately, clinical decisions occur within the specific patient–clinician interaction.²⁴ Table 1 lists each domain’s components, likely impact on overuse, and estimated strength of supporting evidence. Interventions can be conceptualized within appropriate domains or through the interaction between patient and clinician.

We developed a novel and practical conceptual framework for characterizing drivers of overuse and potential intervention points. To our knowledge, this is the first framework incorporating a patient-specific approach to overuse and emphasizing the patient–clinician interaction. Key strengths of framework development are inclusion of a range of perspectives and characterization of the evidence within each domain. Limitations include lack of a formal systematic review and broad, qualitative assessments of evidence strength. However, we believe this framework provides an important conceptual foundation for the study of overuse and interventions to reduce overuse.

Framework Applications

This framework, which highlights the many drivers of overuse, can facilitate understanding of overuse and help conceptualize change, prioritize research goals, and inform specific interventions. For policymakers, the framework can inform efforts to reduce overuse by emphasizing the need for complex interventions and by clarifying the likely impact of interventions targeting specific domains. Similarly, for clinicians and quality improvement professionals, the framework can ground root cause analyses of overuse-related problems and inform allocation of limited resources. Finally, the relatively weak evidence on the role of most acknowledged drivers of overuse suggests an important research agenda. Specifically, several pressing needs have been identified: defining relevant physician and patient cultural factors, investigating interventions to impact culture, defining practice environment features that optimize care appropriateness, and describing specific patient–clinician interaction practices that minimize overuse while providing needed care.

Targeting Interventions

Domains within the framework are influenced by different types of interventions, and different stakeholders may target different domains. For example:
 

• The culture of healthcare consumption may be influenced through public education (eg, Choosing Wisely^® patient resources)^30-32 and public health campaigns.
• The practice environment may be influenced by initiatives to align clinician incentives,³³ team care,³⁴ electronic health record interventions,³⁵ and improved access.³⁶
• Clinician attitudes and beliefs may be influenced by audit and feedback,^37-40 reflection,⁴¹ role modeling,⁴² and education.^43-45
• Patient attitudes and beliefs may be influenced by education, access to price and quality information, and increased engagement in care.^46,47
• For clinicians, the patient–clinician interaction can be improved through training in communication and shared decision-making,25 through access to information (eg, costs) that can be easily shared with patients,^48,49 and through novel visit structures (eg, scribes).⁵⁰
• On the patient side, this interaction can be optimized with improved access (eg, through telemedicine)^51,52 or with patient empowerment during hospitalization.
• The culture of medicine is difficult to influence. Change likely will occur through:

○ Regulatory interventions (eg, Transforming Clinical Practice Initiative of Center for Medicare & Medicaid Innovation).

○ Educational initiatives (eg, high-value care curricula of Alliance for Academic Internal Medicine/American College of Physicians⁵³).

○ Medical journal features (eg, “Less Is More” in JAMA Internal Medicine⁵⁴ and “Things We Do for No Reason” in Journal of Hospital Medicine).

○ Professional organizations (eg, Choosing Wisely^®).

As organizations implement quality improvement initiatives to reduce overuse of services, the framework can be used to target interventions to relevant domains. For example, a hospital leader who wants to reduce opioid prescribing may use the framework to identify the factors that encourage prescribing in each domain—poor understanding of pain treatment (a clinician factor), desire for early discharge encouraging overly aggressive pain management (an environmental factor), patient demand for opioids combined with poor understanding of harms (patient factors), and poor communication regarding pain (a patient–clinician interaction factor). Although not all relevant factors can be addressed, their classification by domain facilitates intervention, in this case perhaps leading to a focus on clinician and patient education on opioids and development of a practical communication tool that targets 3 domains. Table 2 lists ways in which the framework informs approaches to this and other overused services in the hospital setting. Note that some drivers can be acknowledged without identifying targeted interventions.

Moving Forward

Through a multi-stakeholder iterative process, we developed a practical framework for understanding medical overuse and interventions to reduce it. Centered on the patient–clinician interaction, this framework explains overuse as the product of medical and patient culture, the practice environment and incentives, and other clinician and patient factors. Ultimately, care is implemented during the patient–clinician interaction, though few interventions to reduce overuse have focused on that domain.

Conceptualizing overuse through the patient–clinician interaction maintains focus on patients while promoting population health that is both better and lower in cost. This framework can guide interventions to reduce overuse in important parts of the healthcare system while ensuring the final goal of high-quality individualized patient care.

Acknowledgments

The authors thank Valerie Pocus for helping with the artistic design of Framework. An early version of Framework was presented at the 2015 Preventing Overdiagnosis meeting in Bethesda, Maryland.

Disclosures

Dr. Morgan received research support from the VA Health Services Research (CRE 12-307), Agency for Healthcare Research and Quality (AHRQ) (K08- HS18111). Dr. Leppin’s work was supported by CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health (NIH). Dr. Korenstein’s work on this paper was supported by a Cancer Center Support Grant from the National Cancer Institute to Memorial Sloan Kettering Cancer Center (award number P30 CA008748). Dr. Morgan provided a self-developed lecture in a 3M-sponsored series on hospital epidemiology and has received honoraria for serving as a book and journal editor for Springer Publishing. Dr. Smith is employed by the American College of Physicians and owns stock in Merck, where her husband is employed. The other authors report no potential conflicts of interest.

Medical services overuse is the provision of healthcare services for which there is no medical basis or for which harms equal or exceed benefits.¹ This overuse drives poor-quality care and unnecessary cost.^2,3 The high prevalence of overuse is recognized by patients,⁴ clinicians,⁵ and policymakers.⁶ Initiatives to reduce overuse have targeted physicians,⁷ the public,⁸ and medical educators^9,10 but have had limited impact.^11,12 Few studies have addressed methods for reducing overuse, and de-implementation of nonbeneficial practices has proved challenging.^1,13,14 Models for reducing overuse are only theoretical¹⁵ or are focused on administrative decisions.^16,17 We think a practical framework is needed. We used an iterative process, informed by expert opinion and discussion, to design such a framework.

The authors, who have expertise in overuse, value, medical education, evidence-based medicine, and implementation science, reviewed related conceptual frameworks¹⁸ and evidence regarding drivers of overuse. We organized these drivers into domains to create a draft framework, which we presented at Preventing Overdiagnosis 2015, a meeting of clinicians, patients, and policymakers interested in overuse. We incorporated feedback from meeting attendees to modify framework domains, and we performed structured searches (using key words in Pubmed) to explore, and estimate the strength of, evidence supporting items within each domain. We rated supporting evidence as strong (studies found a clear correlation between a factor and overuse), moderate (evidence suggests such a correlation or demonstrates a correlation between a particular factor and utilization but not overuse per se), weak (only indirect evidence exists), or absent (no studies identified evaluating a particular factor). All authors reached consensus on ratings.

Framework Principles and Evidence

Patient-centered definition of overuse. During framework development, defining clinical appropriateness emerged as the primary challenge to identifying and reducing overuse. Although some care generally is appropriate based on strong evidence of benefit, and some is inappropriate given a clear lack of benefit or harm, much care is of unclear or variable benefit. Practice guidelines can help identify overuse, but their utility may be limited by lack of evidence in specific clinical situations,¹⁹ and their recommendations may apply poorly to an individual patient. This presents challenges to using guidelines to identify and reduce overuse.

Despite limitations, the scope of overuse has been estimated by applying broad, often guideline-based, criteria for care appropriateness to administrative data.²⁰ Unfortunately, these estimates provide little direction to clinicians and patients partnering to make usage decisions. During framework development, we identified the importance of a patient-level, patient-specific definition of overuse. This approach reinforces the importance of meeting patient needs while standardizing treatments to reduce overuse. A patient-centered approach may also assist professional societies and advocacy groups in developing actionable campaigns and may uncover evidence gaps.

Centrality of patient-clinician interaction. During framework development, the patient–clinician interaction emerged as the nexus through which drivers of overuse exert influence. The centrality of this interaction has been demonstrated in studies of the relationship between care continuity and overuse²¹ or utilization,^22,23 by evidence that communication and patient–clinician relationships affect utilization,²⁴ and by the observation that clinician training in shared decision-making reduces overuse.²⁵ A patient-centered framework assumes that, at least in the weighing of clinically reasonable options, a patient-centered approach optimizes outcomes for that patient.

Incorporating drivers of overuse. We incorporated drivers of overuse into domains and related them to the patient–clinician interaction.²⁶ Domains included the culture of healthcare consumption, patient factors and experiences, the practice environment, the culture of professional medicine, and clinician attitudes and beliefs.

We characterized the evidence illustrating how drivers within each domain influence healthcare use. The evidence for each domain is listed in Table 1.

The final framework is shown in the Figure. Within the healthcare system, patients are influenced by the culture of healthcare consumption, which varies within and among countries.²⁷ Clinicians are influenced by the culture of medical care, which varies by practice setting,²⁸ and by their training environment.²⁹ Both clinicians and patients are influenced by the practice environment and by personal experiences. Ultimately, clinical decisions occur within the specific patient–clinician interaction.²⁴ Table 1 lists each domain’s components, likely impact on overuse, and estimated strength of supporting evidence. Interventions can be conceptualized within appropriate domains or through the interaction between patient and clinician.

We developed a novel and practical conceptual framework for characterizing drivers of overuse and potential intervention points. To our knowledge, this is the first framework incorporating a patient-specific approach to overuse and emphasizing the patient–clinician interaction. Key strengths of framework development are inclusion of a range of perspectives and characterization of the evidence within each domain. Limitations include lack of a formal systematic review and broad, qualitative assessments of evidence strength. However, we believe this framework provides an important conceptual foundation for the study of overuse and interventions to reduce overuse.

Framework Applications

This framework, which highlights the many drivers of overuse, can facilitate understanding of overuse and help conceptualize change, prioritize research goals, and inform specific interventions. For policymakers, the framework can inform efforts to reduce overuse by emphasizing the need for complex interventions and by clarifying the likely impact of interventions targeting specific domains. Similarly, for clinicians and quality improvement professionals, the framework can ground root cause analyses of overuse-related problems and inform allocation of limited resources. Finally, the relatively weak evidence on the role of most acknowledged drivers of overuse suggests an important research agenda. Specifically, several pressing needs have been identified: defining relevant physician and patient cultural factors, investigating interventions to impact culture, defining practice environment features that optimize care appropriateness, and describing specific patient–clinician interaction practices that minimize overuse while providing needed care.

Targeting Interventions

Domains within the framework are influenced by different types of interventions, and different stakeholders may target different domains. For example:
 

• The culture of healthcare consumption may be influenced through public education (eg, Choosing Wisely^® patient resources)^30-32 and public health campaigns.
• The practice environment may be influenced by initiatives to align clinician incentives,³³ team care,³⁴ electronic health record interventions,³⁵ and improved access.³⁶
• Clinician attitudes and beliefs may be influenced by audit and feedback,^37-40 reflection,⁴¹ role modeling,⁴² and education.^43-45
• Patient attitudes and beliefs may be influenced by education, access to price and quality information, and increased engagement in care.^46,47
• For clinicians, the patient–clinician interaction can be improved through training in communication and shared decision-making,25 through access to information (eg, costs) that can be easily shared with patients,^48,49 and through novel visit structures (eg, scribes).⁵⁰
• On the patient side, this interaction can be optimized with improved access (eg, through telemedicine)^51,52 or with patient empowerment during hospitalization.
• The culture of medicine is difficult to influence. Change likely will occur through:

○ Regulatory interventions (eg, Transforming Clinical Practice Initiative of Center for Medicare & Medicaid Innovation).

○ Educational initiatives (eg, high-value care curricula of Alliance for Academic Internal Medicine/American College of Physicians⁵³).

○ Medical journal features (eg, “Less Is More” in JAMA Internal Medicine⁵⁴ and “Things We Do for No Reason” in Journal of Hospital Medicine).

○ Professional organizations (eg, Choosing Wisely^®).

As organizations implement quality improvement initiatives to reduce overuse of services, the framework can be used to target interventions to relevant domains. For example, a hospital leader who wants to reduce opioid prescribing may use the framework to identify the factors that encourage prescribing in each domain—poor understanding of pain treatment (a clinician factor), desire for early discharge encouraging overly aggressive pain management (an environmental factor), patient demand for opioids combined with poor understanding of harms (patient factors), and poor communication regarding pain (a patient–clinician interaction factor). Although not all relevant factors can be addressed, their classification by domain facilitates intervention, in this case perhaps leading to a focus on clinician and patient education on opioids and development of a practical communication tool that targets 3 domains. Table 2 lists ways in which the framework informs approaches to this and other overused services in the hospital setting. Note that some drivers can be acknowledged without identifying targeted interventions.

Moving Forward

Through a multi-stakeholder iterative process, we developed a practical framework for understanding medical overuse and interventions to reduce it. Centered on the patient–clinician interaction, this framework explains overuse as the product of medical and patient culture, the practice environment and incentives, and other clinician and patient factors. Ultimately, care is implemented during the patient–clinician interaction, though few interventions to reduce overuse have focused on that domain.

Conceptualizing overuse through the patient–clinician interaction maintains focus on patients while promoting population health that is both better and lower in cost. This framework can guide interventions to reduce overuse in important parts of the healthcare system while ensuring the final goal of high-quality individualized patient care.

Acknowledgments

The authors thank Valerie Pocus for helping with the artistic design of Framework. An early version of Framework was presented at the 2015 Preventing Overdiagnosis meeting in Bethesda, Maryland.

Disclosures

Dr. Morgan received research support from the VA Health Services Research (CRE 12-307), Agency for Healthcare Research and Quality (AHRQ) (K08- HS18111). Dr. Leppin’s work was supported by CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health (NIH). Dr. Korenstein’s work on this paper was supported by a Cancer Center Support Grant from the National Cancer Institute to Memorial Sloan Kettering Cancer Center (award number P30 CA008748). Dr. Morgan provided a self-developed lecture in a 3M-sponsored series on hospital epidemiology and has received honoraria for serving as a book and journal editor for Springer Publishing. Dr. Smith is employed by the American College of Physicians and owns stock in Merck, where her husband is employed. The other authors report no potential conflicts of interest.

How do we, as hospitalists, win the hearts and minds of patients, families, and care team members whom we do not know? What are the obstacles that we face when encountering patients and gaining the trust needed to improve patient care and patient experience?

With these questions in mind, the Cultural Humility Work Group, part of SHM’s Practice Management Committee, set out to develop a simple, universal framework to provide a foundation for strengthening communication skills and raising awareness of the basic tenets of cultural humility. According to Tervalon and Murray-Garcia, cultural humility is defined as a “process that requires humility as individuals continually engage in self-reflection and self-critique as lifelong learners and reflective practitioners. It requires humility in how physicians bring into check the power imbalances that exist in the dynamics of physician-patient communication by using patient-focused interviewing and care, and it is a process that requires humility to develop and maintain mutually respectful and dynamic partnerships with communities” (Tervalon, M. & Murray-García, J. “Cultural Humility Versus Cultural Competence: A Critical Distinction in Defining Physician Training Outcomes in Multicultural Education.” J Health Care Poor Underserved. 1998;9[2]:117-25).

• Reflection – Hospitalists will approach every encounter with humility and understanding that there is always something to learn from everyone.
• Respect – Hospitalists will treat every person with the utmost respect and strive to preserve dignity at all times.
• Regard – Hospitalists will hold every person in their highest regard while being aware of and not allowing unconscious biases to interfere in any interactions.
• Relevance – Hospitalists will expect cultural humility to be relevant to the patient and apply this practice to every encounter.
• Resiliency – Hospitalists will embody the practice of cultural humility to enhance personal resilience and globally focused compassion.

The content will be available as a downloadable pocket card that can be easily referenced on rounds and shared with colleagues. Our hope is to achieve heightened awareness of effective interaction. In addition to the definitions of each of the Rs, the card will feature questions to ask yourself before, during, and after every interaction to aid in attaining cultural humility.

The card will be printed and disseminated at Hospital Medicine 2017, and the 5 Rs will be discussed in a few sessions: “Making ‘Everything We Say and Do’ a Positive Patient Experience” in the Practice Management track on Thursday, May 4, and during a 20-minute “MEDtalk” in Product Theater 1 on May 3, at 10:15 a.m.

Keep on the lookout for future blog posts, where you’ll read about the 5 R’s in action through vignettes and a deeper dive into each aspect.

For more information and the downloadable pocket card, visit www.hospitalmedicine.org/5Rs.

Dr. Ansari is associate professor and associate division director of hospital medicine at Loyola University Medical Center, Maywood, Ill., and serves on SHM’s Cultural Humility Work Group.

How do we, as hospitalists, win the hearts and minds of patients, families, and care team members whom we do not know? What are the obstacles that we face when encountering patients and gaining the trust needed to improve patient care and patient experience?

With these questions in mind, the Cultural Humility Work Group, part of SHM’s Practice Management Committee, set out to develop a simple, universal framework to provide a foundation for strengthening communication skills and raising awareness of the basic tenets of cultural humility. According to Tervalon and Murray-Garcia, cultural humility is defined as a “process that requires humility as individuals continually engage in self-reflection and self-critique as lifelong learners and reflective practitioners. It requires humility in how physicians bring into check the power imbalances that exist in the dynamics of physician-patient communication by using patient-focused interviewing and care, and it is a process that requires humility to develop and maintain mutually respectful and dynamic partnerships with communities” (Tervalon, M. & Murray-García, J. “Cultural Humility Versus Cultural Competence: A Critical Distinction in Defining Physician Training Outcomes in Multicultural Education.” J Health Care Poor Underserved. 1998;9[2]:117-25).

• Reflection – Hospitalists will approach every encounter with humility and understanding that there is always something to learn from everyone.
• Respect – Hospitalists will treat every person with the utmost respect and strive to preserve dignity at all times.
• Regard – Hospitalists will hold every person in their highest regard while being aware of and not allowing unconscious biases to interfere in any interactions.
• Relevance – Hospitalists will expect cultural humility to be relevant to the patient and apply this practice to every encounter.
• Resiliency – Hospitalists will embody the practice of cultural humility to enhance personal resilience and globally focused compassion.

The content will be available as a downloadable pocket card that can be easily referenced on rounds and shared with colleagues. Our hope is to achieve heightened awareness of effective interaction. In addition to the definitions of each of the Rs, the card will feature questions to ask yourself before, during, and after every interaction to aid in attaining cultural humility.

The card will be printed and disseminated at Hospital Medicine 2017, and the 5 Rs will be discussed in a few sessions: “Making ‘Everything We Say and Do’ a Positive Patient Experience” in the Practice Management track on Thursday, May 4, and during a 20-minute “MEDtalk” in Product Theater 1 on May 3, at 10:15 a.m.

Keep on the lookout for future blog posts, where you’ll read about the 5 R’s in action through vignettes and a deeper dive into each aspect.

For more information and the downloadable pocket card, visit www.hospitalmedicine.org/5Rs.

Dr. Ansari is associate professor and associate division director of hospital medicine at Loyola University Medical Center, Maywood, Ill., and serves on SHM’s Cultural Humility Work Group.

How do we, as hospitalists, win the hearts and minds of patients, families, and care team members whom we do not know? What are the obstacles that we face when encountering patients and gaining the trust needed to improve patient care and patient experience?

With these questions in mind, the Cultural Humility Work Group, part of SHM’s Practice Management Committee, set out to develop a simple, universal framework to provide a foundation for strengthening communication skills and raising awareness of the basic tenets of cultural humility. According to Tervalon and Murray-Garcia, cultural humility is defined as a “process that requires humility as individuals continually engage in self-reflection and self-critique as lifelong learners and reflective practitioners. It requires humility in how physicians bring into check the power imbalances that exist in the dynamics of physician-patient communication by using patient-focused interviewing and care, and it is a process that requires humility to develop and maintain mutually respectful and dynamic partnerships with communities” (Tervalon, M. & Murray-García, J. “Cultural Humility Versus Cultural Competence: A Critical Distinction in Defining Physician Training Outcomes in Multicultural Education.” J Health Care Poor Underserved. 1998;9[2]:117-25).

• Reflection – Hospitalists will approach every encounter with humility and understanding that there is always something to learn from everyone.
• Respect – Hospitalists will treat every person with the utmost respect and strive to preserve dignity at all times.
• Regard – Hospitalists will hold every person in their highest regard while being aware of and not allowing unconscious biases to interfere in any interactions.
• Relevance – Hospitalists will expect cultural humility to be relevant to the patient and apply this practice to every encounter.
• Resiliency – Hospitalists will embody the practice of cultural humility to enhance personal resilience and globally focused compassion.

The content will be available as a downloadable pocket card that can be easily referenced on rounds and shared with colleagues. Our hope is to achieve heightened awareness of effective interaction. In addition to the definitions of each of the Rs, the card will feature questions to ask yourself before, during, and after every interaction to aid in attaining cultural humility.

The card will be printed and disseminated at Hospital Medicine 2017, and the 5 Rs will be discussed in a few sessions: “Making ‘Everything We Say and Do’ a Positive Patient Experience” in the Practice Management track on Thursday, May 4, and during a 20-minute “MEDtalk” in Product Theater 1 on May 3, at 10:15 a.m.

Keep on the lookout for future blog posts, where you’ll read about the 5 R’s in action through vignettes and a deeper dive into each aspect.

For more information and the downloadable pocket card, visit www.hospitalmedicine.org/5Rs.

Dr. Ansari is associate professor and associate division director of hospital medicine at Loyola University Medical Center, Maywood, Ill., and serves on SHM’s Cultural Humility Work Group.

SAN ANTONIO – About a decade ago, the Northern California Permanente Medical Group realized it had a problem: There were too many open hysterectomies being performed.

“We had a large number of low-volume surgeons doing a lot of open hysterectomies,” said Andrew Walter, MD, a gynecologic surgeon at the Permanente Medical Group (TPMG) campus in Roseville, Calif., part of Kaiser Permanente. Across 15 hospitals in the system, “our open rate was 64% in 2007.”

To address the problem, “our leadership basically set targets; we then provided surgical education and training in minimally invasive hysterectomy,” Dr. Walter said at the annual scientific meeting of the Society of Gynecologic Surgeons.

* The meeting sponsor information was updated 6/9/2017. 

[email protected]

SAN ANTONIO – About a decade ago, the Northern California Permanente Medical Group realized it had a problem: There were too many open hysterectomies being performed.

“We had a large number of low-volume surgeons doing a lot of open hysterectomies,” said Andrew Walter, MD, a gynecologic surgeon at the Permanente Medical Group (TPMG) campus in Roseville, Calif., part of Kaiser Permanente. Across 15 hospitals in the system, “our open rate was 64% in 2007.”

To address the problem, “our leadership basically set targets; we then provided surgical education and training in minimally invasive hysterectomy,” Dr. Walter said at the annual scientific meeting of the Society of Gynecologic Surgeons.

* The meeting sponsor information was updated 6/9/2017. 

[email protected]

SAN ANTONIO – About a decade ago, the Northern California Permanente Medical Group realized it had a problem: There were too many open hysterectomies being performed.

“We had a large number of low-volume surgeons doing a lot of open hysterectomies,” said Andrew Walter, MD, a gynecologic surgeon at the Permanente Medical Group (TPMG) campus in Roseville, Calif., part of Kaiser Permanente. Across 15 hospitals in the system, “our open rate was 64% in 2007.”

To address the problem, “our leadership basically set targets; we then provided surgical education and training in minimally invasive hysterectomy,” Dr. Walter said at the annual scientific meeting of the Society of Gynecologic Surgeons.

* The meeting sponsor information was updated 6/9/2017. 

[email protected]

EXPERT ANALYSIS FROM ECCMID 2017

VIENNA – The first malaria vaccine to enter a national pilot project is not a silver bullet against the disease that kills half a million every year, but it still might be powerful enough to significantly reduce global disease burden, and even impact transmission, according to infectious disease specialist Nick Beeching, MD.

The vaccine, RTS,S (Mosquirix; GlaxoSmithKline), will be tested in three African countries beginning next year, the World Health Organization announced on April 25. The pilot programs will target 720,000 children aged 5-17 months in high-risk areas of the three countries.

Even though it’s the first malaria vaccine to pass its pivotal phase III trial, RTS,S isn’t terribly effective by any standards, said Dr. Beeching of the Royal Liverpool (England) University.

Michele Sullivan/Frontline Medical News

April 25, 2017, is World Malaria Day, and Anthony S. Fauci, MD, and B. Fenton Hall, MD, PhD, of the U.S. National Institute of Allergy and Infectious Diseases, said in a statement, “Safe and effective vaccines are critical tools for future efforts to control, eliminate, and, ultimately, eradicate malaria. NIAID is supporting the development of numerous malaria vaccine candidates, 10 of which are in clinical trials. In 2015, an estimated 212 million new malaria cases and 429,000 deaths occurred. Nearly 90% of these cases were among children under the age of 5 years in Africa, where malaria claims the life of a child every 2 minutes.”

GSK has been working on this vaccine since 1985, according to the company’s RTS,S literature. It is a recombinant protein that targets the circumsporozoite protein of the Plasmodium falciparum parasite at an early stage, before it enters the liver and begins to embed in erythrocytes. The aim, Dr. Beeching said, was to develop an antigen that would mobilize the immune system from the moment a mosquito injected the sporozoites through a bite, “well before they have a chance to hide in the liver.”

The 2- and 3-year follow-up results of the phase III trial, conducted in 15,500 children, were published in the Lancet in 2015. RTS,S was administered as a three-dose series, plus a booster dose, beginning at 5 months of age. The primary immunizations were given with a minimum 4-week interval between doses, with the booster administered 18 months after the last dose.

The primary series reduced clinical cases by 26%. With the booster dose, cases were reduced by 39% overall. The vaccine averted 1,774 episodes of clinical malaria per 1,000 vaccinated children, and 983 cases per 1,000 vaccinated infants. But vaccine efficacy waned over time, disappearing completely in children who got only the three-dose series. The booster dose improved response stability somewhat; during the 12 months after the fourth dose, vaccine efficacy was about 25%.

Based on these results, GSK received approval from the European Medicines Agency in 2015, and the WHO recommended a large-scale implementation of the vaccine be carried out last year. GSK will provide the vaccine at no cost, and each country’s government will decide which regions to include in the pilot study.

This real-world use will put RTS,S to the ultimate test, Dr. Beeching said: “There is always the practical problem of how do you get four doses of vaccine into people. It’s easy to do in a clinical trial, but the operations and the logistics of getting it right on the ground are what really matter. We don’t know how good less than four doses would be, and we still don’t know how long the protective effect of the full series plus booster will last. I think there’s concern that it might wane with time.”

Still, he said, even a 39% reduction in disease burden is worth aggressively pursuing, not only because of the thousands of children’s lives that could be saved, but because unvaccinated children and adults could potentially be protected as well: “We could see a knock-on effect. By reducing the burden of malaria in children, it may also reduce transmission to other people who haven’t been vaccinated.”

The vaccine certainly won’t eradicate malaria, Dr. Beeching said. It needs to be viewed as an addition to WHO’s core vector control strategy, which includes insecticide-impregnated bed nets and mosquito eradication programs.

Cost is an unresolved issue. According to the Malaria Vaccine Initiative, which is partnering with GSK to launch RTS,S, the company won’t charge for the vaccine in the pilot project, and is committed to making sure the children who need it get it.

“In many African countries, childhood vaccines are provided at no cost to children or their families, thanks to existing international and national financing mechanisms,” the company said in a press release. “The RTS,S partnership anticipates that similar mechanisms would be implemented for a malaria vaccine. A shared goal is to have the cost of a malaria vaccine not be a barrier to access.

“GSK has previously stated that the price of RTS,S will cover the cost of manufacturing the vaccine together with a small return of around 5%, which will be reinvested in research and development for next-generation malaria vaccines or vaccines against other neglected tropical diseases.”

Finally, Dr. Beeching said, there’s no way to know to know how long any malaria vaccine would retain its effectiveness.

“Making a malaria vaccine has been a dream for years, and a tough one. The antigens change according to the stage of the parasite, and there is always continuous genetic variation. So there is a possibility of escape from vaccine coverage. These are very clever parasites,” he said.

Dr. Beeching has no financial interest in the vaccine.

[email protected]

On Twitter @Alz_gal

EXPERT ANALYSIS FROM ECCMID 2017

VIENNA – The first malaria vaccine to enter a national pilot project is not a silver bullet against the disease that kills half a million every year, but it still might be powerful enough to significantly reduce global disease burden, and even impact transmission, according to infectious disease specialist Nick Beeching, MD.

The vaccine, RTS,S (Mosquirix; GlaxoSmithKline), will be tested in three African countries beginning next year, the World Health Organization announced on April 25. The pilot programs will target 720,000 children aged 5-17 months in high-risk areas of the three countries.

Even though it’s the first malaria vaccine to pass its pivotal phase III trial, RTS,S isn’t terribly effective by any standards, said Dr. Beeching of the Royal Liverpool (England) University.

Michele Sullivan/Frontline Medical News

April 25, 2017, is World Malaria Day, and Anthony S. Fauci, MD, and B. Fenton Hall, MD, PhD, of the U.S. National Institute of Allergy and Infectious Diseases, said in a statement, “Safe and effective vaccines are critical tools for future efforts to control, eliminate, and, ultimately, eradicate malaria. NIAID is supporting the development of numerous malaria vaccine candidates, 10 of which are in clinical trials. In 2015, an estimated 212 million new malaria cases and 429,000 deaths occurred. Nearly 90% of these cases were among children under the age of 5 years in Africa, where malaria claims the life of a child every 2 minutes.”

GSK has been working on this vaccine since 1985, according to the company’s RTS,S literature. It is a recombinant protein that targets the circumsporozoite protein of the Plasmodium falciparum parasite at an early stage, before it enters the liver and begins to embed in erythrocytes. The aim, Dr. Beeching said, was to develop an antigen that would mobilize the immune system from the moment a mosquito injected the sporozoites through a bite, “well before they have a chance to hide in the liver.”

The 2- and 3-year follow-up results of the phase III trial, conducted in 15,500 children, were published in the Lancet in 2015. RTS,S was administered as a three-dose series, plus a booster dose, beginning at 5 months of age. The primary immunizations were given with a minimum 4-week interval between doses, with the booster administered 18 months after the last dose.

The primary series reduced clinical cases by 26%. With the booster dose, cases were reduced by 39% overall. The vaccine averted 1,774 episodes of clinical malaria per 1,000 vaccinated children, and 983 cases per 1,000 vaccinated infants. But vaccine efficacy waned over time, disappearing completely in children who got only the three-dose series. The booster dose improved response stability somewhat; during the 12 months after the fourth dose, vaccine efficacy was about 25%.

Based on these results, GSK received approval from the European Medicines Agency in 2015, and the WHO recommended a large-scale implementation of the vaccine be carried out last year. GSK will provide the vaccine at no cost, and each country’s government will decide which regions to include in the pilot study.

This real-world use will put RTS,S to the ultimate test, Dr. Beeching said: “There is always the practical problem of how do you get four doses of vaccine into people. It’s easy to do in a clinical trial, but the operations and the logistics of getting it right on the ground are what really matter. We don’t know how good less than four doses would be, and we still don’t know how long the protective effect of the full series plus booster will last. I think there’s concern that it might wane with time.”

Still, he said, even a 39% reduction in disease burden is worth aggressively pursuing, not only because of the thousands of children’s lives that could be saved, but because unvaccinated children and adults could potentially be protected as well: “We could see a knock-on effect. By reducing the burden of malaria in children, it may also reduce transmission to other people who haven’t been vaccinated.”

The vaccine certainly won’t eradicate malaria, Dr. Beeching said. It needs to be viewed as an addition to WHO’s core vector control strategy, which includes insecticide-impregnated bed nets and mosquito eradication programs.

Cost is an unresolved issue. According to the Malaria Vaccine Initiative, which is partnering with GSK to launch RTS,S, the company won’t charge for the vaccine in the pilot project, and is committed to making sure the children who need it get it.

“In many African countries, childhood vaccines are provided at no cost to children or their families, thanks to existing international and national financing mechanisms,” the company said in a press release. “The RTS,S partnership anticipates that similar mechanisms would be implemented for a malaria vaccine. A shared goal is to have the cost of a malaria vaccine not be a barrier to access.

“GSK has previously stated that the price of RTS,S will cover the cost of manufacturing the vaccine together with a small return of around 5%, which will be reinvested in research and development for next-generation malaria vaccines or vaccines against other neglected tropical diseases.”

Finally, Dr. Beeching said, there’s no way to know to know how long any malaria vaccine would retain its effectiveness.

“Making a malaria vaccine has been a dream for years, and a tough one. The antigens change according to the stage of the parasite, and there is always continuous genetic variation. So there is a possibility of escape from vaccine coverage. These are very clever parasites,” he said.

Dr. Beeching has no financial interest in the vaccine.

[email protected]

On Twitter @Alz_gal

EXPERT ANALYSIS FROM ECCMID 2017

VIENNA – The first malaria vaccine to enter a national pilot project is not a silver bullet against the disease that kills half a million every year, but it still might be powerful enough to significantly reduce global disease burden, and even impact transmission, according to infectious disease specialist Nick Beeching, MD.

The vaccine, RTS,S (Mosquirix; GlaxoSmithKline), will be tested in three African countries beginning next year, the World Health Organization announced on April 25. The pilot programs will target 720,000 children aged 5-17 months in high-risk areas of the three countries.

Even though it’s the first malaria vaccine to pass its pivotal phase III trial, RTS,S isn’t terribly effective by any standards, said Dr. Beeching of the Royal Liverpool (England) University.

Michele Sullivan/Frontline Medical News

April 25, 2017, is World Malaria Day, and Anthony S. Fauci, MD, and B. Fenton Hall, MD, PhD, of the U.S. National Institute of Allergy and Infectious Diseases, said in a statement, “Safe and effective vaccines are critical tools for future efforts to control, eliminate, and, ultimately, eradicate malaria. NIAID is supporting the development of numerous malaria vaccine candidates, 10 of which are in clinical trials. In 2015, an estimated 212 million new malaria cases and 429,000 deaths occurred. Nearly 90% of these cases were among children under the age of 5 years in Africa, where malaria claims the life of a child every 2 minutes.”

GSK has been working on this vaccine since 1985, according to the company’s RTS,S literature. It is a recombinant protein that targets the circumsporozoite protein of the Plasmodium falciparum parasite at an early stage, before it enters the liver and begins to embed in erythrocytes. The aim, Dr. Beeching said, was to develop an antigen that would mobilize the immune system from the moment a mosquito injected the sporozoites through a bite, “well before they have a chance to hide in the liver.”

The 2- and 3-year follow-up results of the phase III trial, conducted in 15,500 children, were published in the Lancet in 2015. RTS,S was administered as a three-dose series, plus a booster dose, beginning at 5 months of age. The primary immunizations were given with a minimum 4-week interval between doses, with the booster administered 18 months after the last dose.

The primary series reduced clinical cases by 26%. With the booster dose, cases were reduced by 39% overall. The vaccine averted 1,774 episodes of clinical malaria per 1,000 vaccinated children, and 983 cases per 1,000 vaccinated infants. But vaccine efficacy waned over time, disappearing completely in children who got only the three-dose series. The booster dose improved response stability somewhat; during the 12 months after the fourth dose, vaccine efficacy was about 25%.

Based on these results, GSK received approval from the European Medicines Agency in 2015, and the WHO recommended a large-scale implementation of the vaccine be carried out last year. GSK will provide the vaccine at no cost, and each country’s government will decide which regions to include in the pilot study.

This real-world use will put RTS,S to the ultimate test, Dr. Beeching said: “There is always the practical problem of how do you get four doses of vaccine into people. It’s easy to do in a clinical trial, but the operations and the logistics of getting it right on the ground are what really matter. We don’t know how good less than four doses would be, and we still don’t know how long the protective effect of the full series plus booster will last. I think there’s concern that it might wane with time.”

Still, he said, even a 39% reduction in disease burden is worth aggressively pursuing, not only because of the thousands of children’s lives that could be saved, but because unvaccinated children and adults could potentially be protected as well: “We could see a knock-on effect. By reducing the burden of malaria in children, it may also reduce transmission to other people who haven’t been vaccinated.”

The vaccine certainly won’t eradicate malaria, Dr. Beeching said. It needs to be viewed as an addition to WHO’s core vector control strategy, which includes insecticide-impregnated bed nets and mosquito eradication programs.

Cost is an unresolved issue. According to the Malaria Vaccine Initiative, which is partnering with GSK to launch RTS,S, the company won’t charge for the vaccine in the pilot project, and is committed to making sure the children who need it get it.

“In many African countries, childhood vaccines are provided at no cost to children or their families, thanks to existing international and national financing mechanisms,” the company said in a press release. “The RTS,S partnership anticipates that similar mechanisms would be implemented for a malaria vaccine. A shared goal is to have the cost of a malaria vaccine not be a barrier to access.

“GSK has previously stated that the price of RTS,S will cover the cost of manufacturing the vaccine together with a small return of around 5%, which will be reinvested in research and development for next-generation malaria vaccines or vaccines against other neglected tropical diseases.”

Finally, Dr. Beeching said, there’s no way to know to know how long any malaria vaccine would retain its effectiveness.

“Making a malaria vaccine has been a dream for years, and a tough one. The antigens change according to the stage of the parasite, and there is always continuous genetic variation. So there is a possibility of escape from vaccine coverage. These are very clever parasites,” he said.

Dr. Beeching has no financial interest in the vaccine.

[email protected]

On Twitter @Alz_gal

AMSTERDAM – Long-term treatment with human albumin improved the overall survival of patients with decompensated liver cirrhosis, compared with standard medical care, in a randomized, controlled trial presented at the International Liver Congress.

The final results of the ANSWER study showed that a 38% reduction in the risk of death could be achieved at 18 months’ follow-up by giving patients human albumin, with an overall survival of 78% vs. 66% in the two groups, respectively (hazard ratio, 0.62; 95% confidence interval, 0.40-0.95; P = .028).

“Long-term albumin administration to patients with decompensated cirrhosis may be seen as a disease-modifying treatment,” said the presenting study author, Mauro Bernardi, MD, professor in the department of medical and surgical sciences at the University of Bologna (Italy).

Not only was the overall survival improved, but there was improvement in the management of ascites, a reduction in the incidence of severe complications (such as spontaneous bacterial peritonitis, renal dysfunction, and hepatic encephalopathy), a reduction in the number of hospitalizations and duration of in-hospital treatment, and a signal for improved quality of life, he said.

“We know that it is good to give albumin as an infusion in many, many circumstances,” said Frank Tacke, MD, PhD, who was not involved in the study, during a press briefing at the meeting, sponsored by the European Association for the Study of the Liver (EASL).

“What we did not know before was if there was a role for giving albumin – which is unfortunately quite expensive – for a longer period of time in patients with liver cirrhosis,” said Dr. Tacke, who is the EASL vice-secretary and professor of medicine in the department of gastroenterology, metabolic diseases and intensive care medicine at University Hospital Aachen (Germany).

Although long-term treatment with human albumin is a relatively expensive treatment, particularly because it requires weekly infusion, Dr. Bernardi noted that a cost analysis was being performed, and potentially the cost of treatment could be offset by the reduction in paracentesis, duration of hospitalization, and reduced need for treating patients with complications, compared with standard medical care alone.

“The idea of supplying albumin to patients with advanced cirrhosis is quite an old one, and there is long debate. The point is that a reliable study that could resolve this was simply lacking up to now,” Dr. Bernard said at the briefing.

The results could mean that patients with decompensated cirrhosis now have a much-needed therapeutic option. These patients have “a very poor prognosis,” Dr. Bernardi said. The 1-year probability of survival is about 20%, and the only curative therapy at present is liver transplantation.

A total of 440 patients, mostly male with an average age of 61 years, with cirrhosis and uncomplicated ascites were randomized at 33 Italian centers to receive standard medical treatment alone (n = 213) or with human albumin (n = 218) given at an infused dose of 40 g twice a week for the first 2 weeks, then 40 g every week. The albumin used in the trial was provided by five different pharmaceutical companies and sent to a central location for generic relabeling and distribution out to the participating trial centers.

Significantly fewer patients who were given human albumin than those who were not (66% vs. 38%, P less than .001) needed at least one paracentesis. The incidence rate for the removal of peritoneal fluid in the standard medical treatment arm was 3.5/person per year. There was a 54% reduction in this rate by the addition of human albumin (HR = 0.46; 95% CI, 0.40-0.53; P less than .0001). There was also a significant 46% reduction in the incidence of refractory ascites (48% vs. 25%, P less than .0001).

Patients who received standard medical treatment plus albumin needed fewer hospitalizations and fewer days of in-hospital care per person per year than those in the standard care–only arm. The use of human albumin reduced the number of hospital stays by 35% (HR = 0.65; 95% CI, 0.55-0.77; P less than .0001) and the duration of days in hospital by 45% (HR = 0.55; 95% CI, 0.52-0.58; P less than .0001).

Although not statistically significant, a trend for greater improvements and fewer decreases in quality of life, as measured using the EQ-5D visual assessment scale, at 3, 6, and 12 months, was seen with the use of human albumin.

Four patients had adverse drug reactions: two were mild allergic reactions, and two were potentially life-threatening septic shock that needed intensive care treatment. One of the latter cases might have been caused by pneumonia, and the other required study interruption. But in all cases the patients recovered, Dr. Bernardi reported.

The study was funded by the Italian Drug Agency. Dr. Bernardi had acted as a speaker for and consultant to CLS Behring and Baxter Healthcare, and as a speaker to the Plasma Protein Therapeutics Association’s Europe division, Grifols, Gilead Sciences, and AbbVie Italia. Dr. Tacke had nothing to disclose.

AMSTERDAM – Long-term treatment with human albumin improved the overall survival of patients with decompensated liver cirrhosis, compared with standard medical care, in a randomized, controlled trial presented at the International Liver Congress.

The final results of the ANSWER study showed that a 38% reduction in the risk of death could be achieved at 18 months’ follow-up by giving patients human albumin, with an overall survival of 78% vs. 66% in the two groups, respectively (hazard ratio, 0.62; 95% confidence interval, 0.40-0.95; P = .028).

“Long-term albumin administration to patients with decompensated cirrhosis may be seen as a disease-modifying treatment,” said the presenting study author, Mauro Bernardi, MD, professor in the department of medical and surgical sciences at the University of Bologna (Italy).

Not only was the overall survival improved, but there was improvement in the management of ascites, a reduction in the incidence of severe complications (such as spontaneous bacterial peritonitis, renal dysfunction, and hepatic encephalopathy), a reduction in the number of hospitalizations and duration of in-hospital treatment, and a signal for improved quality of life, he said.

“We know that it is good to give albumin as an infusion in many, many circumstances,” said Frank Tacke, MD, PhD, who was not involved in the study, during a press briefing at the meeting, sponsored by the European Association for the Study of the Liver (EASL).

“What we did not know before was if there was a role for giving albumin – which is unfortunately quite expensive – for a longer period of time in patients with liver cirrhosis,” said Dr. Tacke, who is the EASL vice-secretary and professor of medicine in the department of gastroenterology, metabolic diseases and intensive care medicine at University Hospital Aachen (Germany).

Although long-term treatment with human albumin is a relatively expensive treatment, particularly because it requires weekly infusion, Dr. Bernardi noted that a cost analysis was being performed, and potentially the cost of treatment could be offset by the reduction in paracentesis, duration of hospitalization, and reduced need for treating patients with complications, compared with standard medical care alone.

“The idea of supplying albumin to patients with advanced cirrhosis is quite an old one, and there is long debate. The point is that a reliable study that could resolve this was simply lacking up to now,” Dr. Bernard said at the briefing.

The results could mean that patients with decompensated cirrhosis now have a much-needed therapeutic option. These patients have “a very poor prognosis,” Dr. Bernardi said. The 1-year probability of survival is about 20%, and the only curative therapy at present is liver transplantation.

A total of 440 patients, mostly male with an average age of 61 years, with cirrhosis and uncomplicated ascites were randomized at 33 Italian centers to receive standard medical treatment alone (n = 213) or with human albumin (n = 218) given at an infused dose of 40 g twice a week for the first 2 weeks, then 40 g every week. The albumin used in the trial was provided by five different pharmaceutical companies and sent to a central location for generic relabeling and distribution out to the participating trial centers.

Significantly fewer patients who were given human albumin than those who were not (66% vs. 38%, P less than .001) needed at least one paracentesis. The incidence rate for the removal of peritoneal fluid in the standard medical treatment arm was 3.5/person per year. There was a 54% reduction in this rate by the addition of human albumin (HR = 0.46; 95% CI, 0.40-0.53; P less than .0001). There was also a significant 46% reduction in the incidence of refractory ascites (48% vs. 25%, P less than .0001).

Patients who received standard medical treatment plus albumin needed fewer hospitalizations and fewer days of in-hospital care per person per year than those in the standard care–only arm. The use of human albumin reduced the number of hospital stays by 35% (HR = 0.65; 95% CI, 0.55-0.77; P less than .0001) and the duration of days in hospital by 45% (HR = 0.55; 95% CI, 0.52-0.58; P less than .0001).

Although not statistically significant, a trend for greater improvements and fewer decreases in quality of life, as measured using the EQ-5D visual assessment scale, at 3, 6, and 12 months, was seen with the use of human albumin.

Four patients had adverse drug reactions: two were mild allergic reactions, and two were potentially life-threatening septic shock that needed intensive care treatment. One of the latter cases might have been caused by pneumonia, and the other required study interruption. But in all cases the patients recovered, Dr. Bernardi reported.

The study was funded by the Italian Drug Agency. Dr. Bernardi had acted as a speaker for and consultant to CLS Behring and Baxter Healthcare, and as a speaker to the Plasma Protein Therapeutics Association’s Europe division, Grifols, Gilead Sciences, and AbbVie Italia. Dr. Tacke had nothing to disclose.

AMSTERDAM – Long-term treatment with human albumin improved the overall survival of patients with decompensated liver cirrhosis, compared with standard medical care, in a randomized, controlled trial presented at the International Liver Congress.

The final results of the ANSWER study showed that a 38% reduction in the risk of death could be achieved at 18 months’ follow-up by giving patients human albumin, with an overall survival of 78% vs. 66% in the two groups, respectively (hazard ratio, 0.62; 95% confidence interval, 0.40-0.95; P = .028).

“Long-term albumin administration to patients with decompensated cirrhosis may be seen as a disease-modifying treatment,” said the presenting study author, Mauro Bernardi, MD, professor in the department of medical and surgical sciences at the University of Bologna (Italy).

Not only was the overall survival improved, but there was improvement in the management of ascites, a reduction in the incidence of severe complications (such as spontaneous bacterial peritonitis, renal dysfunction, and hepatic encephalopathy), a reduction in the number of hospitalizations and duration of in-hospital treatment, and a signal for improved quality of life, he said.

“We know that it is good to give albumin as an infusion in many, many circumstances,” said Frank Tacke, MD, PhD, who was not involved in the study, during a press briefing at the meeting, sponsored by the European Association for the Study of the Liver (EASL).

“What we did not know before was if there was a role for giving albumin – which is unfortunately quite expensive – for a longer period of time in patients with liver cirrhosis,” said Dr. Tacke, who is the EASL vice-secretary and professor of medicine in the department of gastroenterology, metabolic diseases and intensive care medicine at University Hospital Aachen (Germany).

Although long-term treatment with human albumin is a relatively expensive treatment, particularly because it requires weekly infusion, Dr. Bernardi noted that a cost analysis was being performed, and potentially the cost of treatment could be offset by the reduction in paracentesis, duration of hospitalization, and reduced need for treating patients with complications, compared with standard medical care alone.

“The idea of supplying albumin to patients with advanced cirrhosis is quite an old one, and there is long debate. The point is that a reliable study that could resolve this was simply lacking up to now,” Dr. Bernard said at the briefing.

The results could mean that patients with decompensated cirrhosis now have a much-needed therapeutic option. These patients have “a very poor prognosis,” Dr. Bernardi said. The 1-year probability of survival is about 20%, and the only curative therapy at present is liver transplantation.

A total of 440 patients, mostly male with an average age of 61 years, with cirrhosis and uncomplicated ascites were randomized at 33 Italian centers to receive standard medical treatment alone (n = 213) or with human albumin (n = 218) given at an infused dose of 40 g twice a week for the first 2 weeks, then 40 g every week. The albumin used in the trial was provided by five different pharmaceutical companies and sent to a central location for generic relabeling and distribution out to the participating trial centers.

Significantly fewer patients who were given human albumin than those who were not (66% vs. 38%, P less than .001) needed at least one paracentesis. The incidence rate for the removal of peritoneal fluid in the standard medical treatment arm was 3.5/person per year. There was a 54% reduction in this rate by the addition of human albumin (HR = 0.46; 95% CI, 0.40-0.53; P less than .0001). There was also a significant 46% reduction in the incidence of refractory ascites (48% vs. 25%, P less than .0001).

Patients who received standard medical treatment plus albumin needed fewer hospitalizations and fewer days of in-hospital care per person per year than those in the standard care–only arm. The use of human albumin reduced the number of hospital stays by 35% (HR = 0.65; 95% CI, 0.55-0.77; P less than .0001) and the duration of days in hospital by 45% (HR = 0.55; 95% CI, 0.52-0.58; P less than .0001).

Although not statistically significant, a trend for greater improvements and fewer decreases in quality of life, as measured using the EQ-5D visual assessment scale, at 3, 6, and 12 months, was seen with the use of human albumin.

Four patients had adverse drug reactions: two were mild allergic reactions, and two were potentially life-threatening septic shock that needed intensive care treatment. One of the latter cases might have been caused by pneumonia, and the other required study interruption. But in all cases the patients recovered, Dr. Bernardi reported.

The study was funded by the Italian Drug Agency. Dr. Bernardi had acted as a speaker for and consultant to CLS Behring and Baxter Healthcare, and as a speaker to the Plasma Protein Therapeutics Association’s Europe division, Grifols, Gilead Sciences, and AbbVie Italia. Dr. Tacke had nothing to disclose.